In vitro model development for novel prevention measures against foodborne pathogens by Van Tassell, Maxwell L
  
IN VITRO MODEL DEVELOPMENT FOR NOVEL PREVENTION MEASURES  
AGAINST FOODBORNE PATHOGENS 
 
 
 
 
 
 
BY 
 
MAXWELL L. VAN TASSELL 
 
 
 
 
 
 
 
DISSERTATION 
 
Submitted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy in Food Science and Human Nutrition 
with a concentration in Food Science 
in the Graduate College of the  
University of Illinois at Urbana-Champaign, 2016 
 
 
 
Urbana, Illinois 
 
 
Doctoral Committee: 
 
Associate Professor Yong-Su Jin, Chair 
Associate Professor Michael J. Miller, Director of Research 
Professor H. Rex Gaskins 
Professor Emeritus Hans-Peter M. Blaschek 
 
 
ii 
 
ABSTRACT 
Foodborne disease prevention can benefit from improved antimicrobial applications and 
targeted approaches to investigating phenomena that drive the presence and absence of 
pathogens in our foods. The use of suboptimal methodologies for these investigations remains a 
hurdle to furthering preventative capabilities in many food and health systems. My dissertation 
research has featured the development of methods for better modeling the interactions between 
pathogens and their environment, so that antimicrobial measures can be discovered and validated 
more accurately. 
Interest in the use of probiotics to prevent microbial infection is growing rapidly, 
particularly considering the global rise in antibiotic resistance of various pathogens. Probiotics 
are microorganisms that promote health when consumed, via a number of possible mechanisms 
including the prevention of pathogen carriage and infection. Adhesion to intestinal cells has been 
widely used as a criterion for the selection of probiotics. This is in part due to the assumption 
that adhesion of probiotics to host tissues prevents pathogen attachment and thereby 
pathogenesis. However, unlike antimicrobial production, adhesion has not been well 
characterized as a competitive exclusion mechanism. Mechanisms of adhesion to host tissue 
have been intensively studied in numerous pathogens, such as Escherichia coli and 
Pseudomonas aeruginosa, and many are mediated by attachment to oligo- and polysaccharide 
components found on the mucosal surfaces of host tissues. However, the role these types of 
glycans play in the adhesion of non-pathogens has only recently begun to be investigated. In 
Chapter 1, I detail the potential contributions of muco-adhesion to the probiotic effect of 
lactobacilli and highlight the importance of glycan-mediated interactions that are often 
overlooked in in vitro characterization of organisms. Specific adhesion mechanisms are still 
poorly understood, largely due to the prohibitive costs of complex oligosaccharides or 
glycomimetics. Studies of probiotic adhesion are also often confounded by multiple potential 
mechanisms at play and even when investigating glycan-specific models, whole-cell interactions 
have shown limited success. 
Effective control strategies for pathogens within production animal reservoirs could 
significantly limit human foodborne disease. Poultry comprise one such prominent reservoir, the 
primary source of Campylobacteri jejuni in developed nations. Fucosylated oligosaccharides 
have been implicated in the competitive exclusion of C. jejuni from host gastrointestinal tracts, 
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suggesting that glycan-mediated adhesion facilitates colonization and infection. However, such 
mechanisms are difficult to model in vitro independent of confounding interactions, especially in 
a way that maintains wild-type functionality and facilitates cell manipulation further. I developed 
a flexible glycan-specific affinity chromatography method to address this constraint, by 
simplifying and isolating bacteria-glycan interactions. Chapter 2 details the use and validation of 
this model by demonstrating the adhesion of E. coli and C. jejuni to specific carbohydrate 
structures, namely mannose and 2-fucosyllactose respectively. Subpopulations of E. coli, for 
example, could be separated based on the predominance of mannose-binding fimbriae. The 
mechanism by which C. jejuni adheres to fucose remains to be determined, but the development 
of this model serves as a step towards understanding novel mechanisms that can be exploited for 
establishing and optimizing competitive interactions between target pathogens and probiotics. 
In pursuit of a more applied approach to food safety, I also sought to address a major 
concern of Hispanic-style fresh cheeses, which are prone to carriage of one of the deadliest 
known foodborne pathogens, Listeria monocytogenes. Soft cheeses such as queso fresco are 
linked to approximately a quarter of US listeriosis cases annually, largely due to a lack of 
intrinsic factors within these cheeses (e.g. high acidity or salt, low moisture) that would prevent 
listerial growth. Given the ability of L. monocytogenes to grow under refrigeration, and the 
negative impact of thermal or high-pressure processing on product quality, additional measures 
for preventing listerial proliferation are highly desirable. I developed a miniature laboratory-scale 
queso fresco model to accommodate the assessment of novel antimicrobial compounds that are 
often available only in limited amounts. This model also allows for greater control over 
production parameters and biocontainment relative to alternative methods, opening the door to 
answer questions of the interaction between bacterial contaminants, antimicrobial measures, and 
their food environment. As described in Chapter 3, we initially validated the model by assessing 
the antilisterial efficacy of the food-grade bacteriocin nisin, as well as ferulic acid. Both 
compounds limited the growth of Listeria over a three-week refrigerated shelf life, but were 
unable to completely halt the growth of contaminants.  
In search for more effective means of killing L. monocytogenes, bacteriophage endolysins 
were identified to have considerable potential for overcoming limitations of other antimicrobials 
in foods such as fresh cheeses. Endolysins are peptidoglycan hydrolases that lyse bacteria as part 
of the bacteriophage lytic cycle. They do not promote bacterial resistance like bacteriophages, 
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bacteriocins, or antibiotics, still demonstrate specificity for target organisms, should not impact 
food quality like organic acids and extracts might, and have activity within higher pH ranges as 
well. There has been much recent investigation of endolysins as antimicrobials, which has 
resulted in the documentation of numerous ways in which they may be optimized for 
antimicrobial efficacy via bioengineering. Chapter 4 discusses intrinsic and extrinsic variables 
that affect the antimicrobial potential of an endolysin, including several elements of endolysin 
structure, environmental conditions, and target cell physiology. However, many of these 
variables have not been well characterized, particularly the relationships between cell 
physiology, sensitivity to lysis, and environmental factors relevant to food applications. 
To characterize factors that contribute to enzymatic activity and cell sensitivity, I 
observed the interaction of the recombinant endolysin PlyP100 with Listeria under various 
experimental conditions in vitro. Chapter 5 shows that PlyP100 exhibits environmental 
tolerances compatible with application in fresh cheeses, which was confirmed in the miniaturized 
queso fresco model. Treatment of PlyP100 in cheeses contaminated with L. monocytogenes 
completely prevented growth over four weeks under refrigeration. Furthermore, I show that 
endolysin sensitivity is dependent upon cell history with regards to growth conditions, cell cycle, 
and likely growth rate. 
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CHAPTER 1: LACTOBACILLUS ADHESION TO MUCUS1 
1.1 ABSTRACT 
Mucus provides protective functions in the gastrointestinal tract and plays an important 
role in the adhesion of microorganisms to host surfaces. Mucin glycoproteins polymerize, 
forming a framework to which certain microbial populations can adhere, including probiotic 
Lactobacillus species. Numerous mechanisms for adhesion to mucus have been discovered in 
lactobacilli, including partially characterized mucus binding proteins. These mechanisms vary in 
importance with the in vitro models studied, which could significantly affect the perceived 
probiotic potential of the organisms. Understanding the nature of mucus-microbe interactions 
could be the key to elucidating the mechanisms of probiotic adhesion within the host. 
1.2 INTRODUCTION 
Lactobacilli are of significant importance to food industries due to their involvement in 
the production of various fermented dairy, meat, and vegetable foods. Also important to the 
health industry, lactobacilli are used as probiotics due to their health-promoting effects when 
consumed. One of the frequently exploited activities used to screen probiotic candidates is 
adhesion to the host gut, which is presumed to be requisite for sufficient host-interaction to 
confer health benefits [1]. Various in vitro models are used for the study of bacterial adhesion 
because of the complexity of studying the in vivo system. However, these models are 
simplifications of in vivo situations, resulting in limited conclusions. One significant aspect of 
the gastrointestinal (GI) tract that is easy to overlook when studying bacterial adhesion, and 
choosing models with which to measure adhesion, is the presence of a mucus layer between the 
lumen and GI epithelial cells. The presence of mucus is particularly relevant in the colon, where 
mucus is thickest and microorganisms are most abundant. 
The layer of mucus bound to GI epithelia is formed from a continuous gel matrix 
composed primarily of complex glycoproteins that acts as a barrier to protect the host from 
harmful antigens and promote luminal motility. This layer of mucus is the first physical barrier to 
host-cell stimulation by bacteria in the gut. Adhesion to this mucus is therefore the first step 
required for probiotic organisms to interact with host cells and elicit any particular response. In 
                                                 
1 This chapter appeared in its entirety in the journal Nutrients: Van Tassell M.L. and Miller M.J., 2011. 
Lactobacillus Adhesion to Mucus. Nutrients. 3, 613-636. It is available open-access online at http://www.mdpi.com/ 
and using DOI: 10.3390/nu3050613.  
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the human intestinal tract, the layer of mucus may vary in thickness from about 30 to 300 µm, 
generally increasing in thickness from the small intestine to the rectum, but the layer of mucus 
most closely bound to the epithelial layer rarely contains any bacteria at all [2,3]. 
Numerous studies have characterized interactions between bacteria and host epithelia that 
induce alterations in host mucosal response [4,5,6] but how changes in mucus composition affect 
adhesion by gut microorganisms is not well understood. Likewise, exposure to mucus during 
growth has been shown to affect bacterial gene expression [7], but resulting changes to adhesion 
are not well recognized. Additionally, existing studies for bacterial adhesion show great 
variability due to a lack of standardization, complicating the interpretation of data from the 
current literature [8]. 
In this review, we will examine the composition of the mucus layers protecting GI 
epithelial tissue, which is considered to be the primary location of host-probiotic interaction [9]. 
Our focus will be on its relevance to Lactobacillus species, commensal bacteria of the human gut 
that are used extensively in commercial probiotic supplements and contain the most widely 
studied probiotic species in scientific literature. Our goal is to provide a framework for a better 
understanding of the role that mucus plays in probiotic-host interactions. 
1.3 INTESTINAL MUCUS 
The epithelial tissue that forms the lining of the intestine is composed of various 
columnar cell types. Scattered across the length of the intestine, and all mucosal tissues, are 
goblet cells. These cells are unicellular glands that produce glycoproteins called mucins, which 
give mucus its characteristic viscoelastic physical properties. Secreted mucins polymerize to 
form the matrix that provides the structural foundation of the mucus layer resulting in protection 
from pathogens, enzymes, toxins, dehydration and abrasion [10]. Goblet cells produce secretory 
mucin at a basal constitutive level under normal physiological conditions to maintain this 
protective layer of mucus, which is exposed to the harsh luminal environment and constantly 
eroded by luminal particulates and intestinal peristalsis [11].  
Table 1.1 shows a reported 21 MUC genes code for the protein cores of mucins in 
humans. Gastrointestinal mucins are either translocated to the membrane surface or secreted into 
the mucous gel. Mucins are also either neutral or acidic, depending on their glycosyl 
modification. These categories can be further subdivided to account for greater variation in 
mucin structure [12].  
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Gastrointestinal MUC proteins contain characteristic tandem repeats of threonine, 
proline, and serine residues, where O-glycosidic linkages occur between the protein core and N-
acetylgalactosamine (GalNAc) termini of oligosaccharides [46,47]. Neither the amino nor the 
carboxy termini of secretory mucins are generally glycosylated [48], but contain cysteine rich 
regions that promote intermolecular disulfide bonding (as shown in Figure 1.1). The dense 
glycosylation of the protein core and intermolecular bonding of the terminal regions effectively 
protects the mucin polymers from protease activity, preserving the protective structural matrix 
[49]. 
The predominant genes expressing membrane-bound mucins in human colonic goblet 
cells are MUC1, MUC3A/B, MUC4, and MUC12. Membrane-bound mucins could play a role in 
immunomodulatory effects of bacterial interactions with the epithelial membrane when the 
secretory mucin matrix is bypassed [50], however bacteria more frequently come in contact with 
secretory mucins considering the majority of bacteria only inhabit the outer portions of the 
mucus layers [51]. MUC2 is the principal secretory mucin gene expressed in the colon, 
comprising the majority of the mucous gel protecting the underlying tissue [52]. The role and 
mechanisms of mucin in innate immunity is reviewed more thoroughly by Dharmani et al. [53] 
and for a more detailed structural analysis of MUC2, see Allen et al. [15].  
Oligosaccharide chains are affixed to MUC proteins by membrane-bound transferases in 
the Golgi apparatus and endoplasmic reticulum of goblet cells. GalNAc is affixed to the mucin 
protein from a sugar-nucleotide donor and a collection of specific glycosyltransferases continues 
to add residues, resulting in an oligosaccharide with a particular structure and terminus [54,55]. 
Glycosylation biosynthesis pathways are highly complex; glycosyltransferase gene expression 
levels, variability in spatiotemporal concentrations of enzymes, cofactors, and substrates, as well 
as the number of branching configurations possible all contribute to the wide range of potential 
protein-modifications [55]. This leads to glycoproteins forming from the same mucin gene 
product that will vary in glycan modification with location or tissue. 
The oligosaccharide modifications can comprise up to 80% of the weight of a mucin and 
vary in length and structure. Secreted colonic mucins commonly contain side-chains of 4–15 
monosaccharides with galactose and GalNAc backbones and branched chains terminating with 
GalNAc, fucose, or sialic (neuraminic) acid to varying degrees [56,57].  
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The predominance of acidic mucin subtypes, those with side-chains containing terminal 
ester sulfates and sialic acid groups, varies by location in the GI tract from species to species, as 
does the type of acidic modification most heavily expressed [58]. The presence of acidic side-
chains can result in greater inhibition of bacterial growth in vitro [59] and reduced enzymatic 
degradation [60,61], but what causes the prevalence of these modifications in different parts of 
GI tissues is likely due to the tissue-dependence of specific collections of glycosyltransferase 
enzymes [62].  
Intestinal mucin polymers are considered nutritive glycans for commensal bacteria in the 
promotion of their residence and associated benefits [63,64]. Host glycosylation patterns in the 
gut may have coevolved with intestinal microbiota to accommodate the filling of niches 
beneficial to the host [65,66]. Host provision of mucin oligosaccharides specific to particular 
bacterial enzymes could provide a nutritional advantage to bacteria with those enzymes and 
differential expression of mucin oligosaccharides by tissue could hypothetically regulate host-
microbe interactions to direct certain microbial populations to fill particular host-niches. So-
called host ―legislation‖ of glycosylation to promote particular microbial populations is 
evaluated in greater depth in a review by Patsos and Corfield [67]. Whether this plays a crucial 
role in Lactobacillus adhesion or is primarily a mechanism of promoting maintenance of other 
commensal microbiota is currently unclear.  
One broad example of host legislation comes from the analysis of mucin oligosaccharide 
composition along the human intestinal tract, which showed that certain glycosylation patterns 
were conserved regionally despite inter-individual variation [68]. A gradient of sialylated mucin 
concentration was observed, decreasing from the ileum to the colon, running against an 
increasing gradient of more heavily fucosylated mucin.  
A more specific example of microbial legislation by hosts lies in the presence of O-
glycans on mucin that exhibit Lewis type or blood group ABO antigens. The secretor genes that 
determine host blood type also control the specificity of the ABO blood group type terminal 
glycosides of certain mucin oligosaccharide chains [69]. The glycosyltransferase responsible for 
blood group antigen precursors has been identified in secretory tissues producing mucins and 
glycoproteins [70]. There is evidence that populations of bacteria that produce specific blood 
type antigen-degrading glycosidases are present at levels 50,000 times greater in individuals with 
that particular blood type [71].  
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While evidence of mucin oligosaccharide degradation by bacteria is fairly well 
established [64,72–75], the dramatic impact of blood type on the composition of enteric 
microbial populations could imply that there is some degree of binding preference at play with 
host glycan legislation as well. This is supported by evidence of bacteria binding with human 
milk oligosaccharides, which can exhibit structural similarities with mucin oligosaccharides and 
blood type antigens [76].  
Glycosidases of lactic acid bacteria have been fairly well characterized in terms of 
oligosaccharide breakdown and metabolism [77,78], but knowledge of glycoconjugate adhesion 
remains poorly described. Figure 1.2 displays a model of molecular binding mechanisms that 
may play a role in host-bacteria interactions. Elucidation of these binding mechanisms may be 
the key to understanding adhesion of lactobacilli in the gut. 
For a more detailed characterization of mucin production, structure, and host function see 
the review by Lindén et al. [79]. Further information on the study of mucin glycomics, including 
identified O-linked glycan modifications characteristic of GI mucin and their biosynthetic 
pathways, can be obtained from glycobiology resources such as the Kyoto Encyclopedia of 
Genes and Genomes [80] and the Consortium for Functional Glycomics [81]. 
1.4 ADHESION 
Most clinical studies of probiotic persistence and colonization show that probiotic 
organisms do not permanently colonize the GI tract and continue providing their hosts benefits 
only for brief periods after they have stopped being administered [82,83]. Little is known of what 
makes probiotic organisms so transient relative to commensals, so it is important to consider the 
factors influencing their capability to adhere and persist in the gut when studying and 
manipulating probiotic organisms. Bacteria adhere initially to GI surfaces by nonspecific 
physical interactions, such as steric and hydrophobic interactions, which result in reversible 
attachment. Several researchers have reported that there is a degree of correlation between 
hydrophobicity and adhesion to the hydrophobic mucosal surface [84–87]. However, other 
studies indicated that there was no correlation between cell surface hydrophobicity and adhesion 
to intestinal mucus [88,89]. In these studies, highly adhesive bacteria demonstrated fairly low 
surface hydrophobicities. This has suggested that cell surface hydrophobicity is not an accurate 
measure of adhesive potential.  
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While adhesive characteristics of lactobacilli vary considerably among strains and species 
[90–92], many have large surface proteins with highly repetitive structures that are involved in 
mucus adhesion. Though specific mechanisms are not yet well understood, evidence suggests 
that carbohydrate-protein interactions play a key role in the adhesion of these proteins to mucin-
bound oligosaccharides, especially considering numerous mucus-binding proteins contain 
regions homologous with binding domains of other known proteins such as lectins. The 
evolution of lectin-like adhesins in endosymbiotic bacteria may have been favored by the 
presence of multivalent substrates such as the mucins found in the GI tract. Affinities of lectins 
for multivalent glycoproteins can be 50-fold to 106-fold greater than for individual glycan 
moieties [93]. Recently, a number of mucus-binding proteins have been isolated, some of which 
have been shown to display lectin-like interactions, and some of which may be conserved in 
numerous Lactobacillus species.  
1.4.1 Mucus Binding Proteins. 
Several lactobacilli proteins have been shown to promote mucus adhesion (Table 1.2). 
The most studied example of mucus-targeting bacterial adhesins is the mucus-binding protein, 
MUB, produced by L. reuteri [82,94]. The MUB protein contains repeated functional domains, 
referred to by the authors as Mub domains, which are responsible for the protein’s adhesive 
properties. The Mub domain has since been designated a member of the MucBP domain family 
(Pfam PF06458). Numerous MUB homologues and MucBP domain containing proteins have 
been found, but almost exclusively in lactic acid bacteria and predominantly in lactobacilli found 
naturally in intestinal niches (Table 1.3). This suggests that MucBP domain containing proteins 
play an important role in establishing host-microbial interactions in the gut and promoted the 
evolution of the species as primarily GI organisms [93,95–97]. 
MUB and most MucBP domain containing proteins exhibit characteristics typical of 
Gram-positive cell surface proteins; a C-terminal sortase recognition motif (LPXTG) for 
anchoring the protein to peptidoglycan, repeated functional domains and an N-terminal region 
signaling the protein for secretion [94,95].  
Roos and Jonsson’s competitive adhesion study showed that the binding of MUB to 
mucus was inhibited by the glycoproteins fetuin and asialofetuin as well as fucose, suggesting 
that MUB interacts with specific muco-oligosaccharides [94]. The study also demonstrated 
equivalent adhesion to mucus from different hosts indicating that MUB binding has little to no 
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host specificity regarding mucus components. The recent resolution of the crystal structure of a 
MucBP domain in MUB, dubbed Mub2 [92], and subsequent discovery of immunoglobulin 
binding, provides further evidence of a broad binding specificity. This suggests that binding 
specificities of MucBP domain containing proteins are dictated by multiple factors, not solely 
resulting from the presence of MucBP domains.  
Fimbrial genes have been reported in L. johnsonii NCC533 [99], but the direct 
visualization of pili on Lactobacillus cells has only been shown for L. rhamnosus GG [100]. 
Fimbriae, also referred to as pili, are thin proteinaceous extensions from bacterial cells, 
predominantly in Gram-negative bacteria, that promote adhesion. In many pathogens, pili are 
virulence factors that promote attachment to the host [101]. Kankainen et al. [100] isolated a 
pilin subunit, SpaC, located within the pili structure and found at the pilus tip, which was 
concluded to be essential to the interaction of L. rhamnosus GG with host mucus. A mutant 
strain lacking spaC expression showed significantly reduced binding. While these genes are 
uncommon among lactobacilli, this study has shown for the first time that fimbrial interaction 
with mucus can mediate host adhesion in lactobacilli.  
SlpA, an S-layer protein in L. acidophilus, has been implicated in promoting adhesion 
directly to the GI surface, because slpA knockouts showed decreased adhesion capability [103]. 
However, this could possibly be due to disruption of other surface proteins. S-layer proteins and 
glycoproteins can form a latticed monolayer coating the surface of bacterial cells [114]. S-layer 
components can vary widely by species, but function to protect the cell from enzymatic damage, 
low pH, bacteriophages and phagocytosis. While S-layers are present in only some Lactobacillus 
species, they are beginning to be studied for their adhesive functions. A number of studies have 
begun associating S-layer proteins in probiotic bacteria with competitive exclusion of pathogens 
and pathogen adhesion to mucus [115–117].  
Certain other surface proteins are implicated in contributing to adhesive properties of 
lactobacilli but are otherwise not well characterized or their importance to adhesive mechanisms 
is poorly defined. For instance, a 32 kDa protein associated with adhesion to porcine mucus in L. 
fermentum, named 32-Mmubp, was identified as a homologue of the substrate binding domains 
of the OpuAC ABC-transport protein family [102]. A mannose-specific adhesin protein (Msa, a 
MucBP domain containing protein) is responsible for the binding of mannose by L. plantarum 
[104]. While this was initially discovered as a protein responsible for agglutinating 
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Saccharomyces cerevisiae, the presence of L. plantarum in many intestinal niches suggests that 
the MucBP domains of Msa may also play a role in adhesion to non-mannosylated muco-
oligosaccharides as well. Elongation Factor Tu is a guanosine binding protein that is important in 
protein synthesis in the cytoplasm, but has been identified as a membrane associated protein as 
well [107,108]. More recently it has been found on the cell surfaces of many lactobacilli 
[109,110] and the demonstration of its upregulation in the presence of mucus suggests it may 
play a role in adhesion to the GI tract [111]. Mucus adhesion-promoting protein (MapA) is 
reported to mediate the binding of L. reuteri and L. fermentum to mucus [105,106]. Interestingly, 
it is also degraded into an antimicrobial peptide, which lends the host anti-pathogenic properties 
and provides an example of how large surface proteins may exhibit evolutionarily beneficial 
pleiotropic effects [118]. 
1.4.2 Factors that Influence Binding in vivo and in vitro. 
Numerous factors have been shown to influence binding of lactobacilli to mucus in vitro. 
Certain aspects of experimental design in particular should be reviewed when choosing or 
comparing methods to study adhesion in vitro because of the direct effects they have on 
adhesion. Time allotted for incubation of bacteria on immobilized mucus can have a significant 
influence on observed adhesion if microbial sedimentation occurs and the substrate is saturated 
at an artificial level [119].  
Ramiah et al. [111] showed that growth conditions mimicking the GI environment have 
significant effects on the expression of several mucus adhesins in vitro in L. plantarum. MapA 
was upregulated 6–8-fold when incubated in the presence of mucin and up to 25-fold when 
exposed to physiological concentrations of pancreatin and bile compared to MRS grown 
controls. It was also found that mapA was significantly downregulated in the presence of 
cysteine, and suggested that cysteine is an effector molecule that represses transcription of mapA. 
Mub was expressed 80–140-fold more in the presence of mucin, but was suppressed 7–30-fold 
under normal gut physiological conditions containing bile and pancreatin. EF-Tu was expressed 
33–100 times greater in media containing mucus, but was not affected by bile or pancreatin 
concentrations. This may connote interplay between different mechanisms regulating adhesin 
expression to adapt to particular environments.  
The possible mechanisms whereby food components affect the adhesion of probiotic 
organisms in vivo have not been investigated thoroughly. Exposure to milk and milk fatty acids 
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has been observed to reduce the adhesive properties of some probiotic lactobacilli [120,121] to 
human intestinal mucus in vitro, which may also be relevant in vivo. It is also hypothesized that 
entrapment in food matrices in vivo, resulting in binding to or steric hindrance of adhesins, can 
decrease adhesion of bacteria to intestinal surfaces [119].  
All bacterial adhesion in the gut is also likely inhibited to some degree by competitive 
exclusion of access to binding sites by commensal organisms, but quantification of these effects 
have yet to be studied thoroughly. 
1.5 IN VITRO MODELS 
Adhesion to the GI tract has been widely used as a criterion for the selection of probiotic 
lactobacilli [122]. It has generally been assumed that probiotic efficacy is enhanced by adhesion 
to the GI tract, which increases residence time in vivo. This extends the period during which 
probiotic organisms can exert beneficial effects, such as immune stimulation from contact with 
the intestinal tract [123,124]. However, it is difficult to link adhesion, specifically, with probiotic 
efficacy. Studies with isogenic strains containing adhesion factor knockouts [125] demonstrate 
decreased adhesion to the gut, however it is not known how such a knockout would alter 
probiotic efficacy. Adhesion has been demonstrated as an important factor in the displacement of 
pathogens by probiotic bacteria in vitro [126–128], but isolating the influence of adhesion in vivo 
is complicated by various confounded factors. The effects of probiotic bacteria stem not only 
from adhesion to the GI tract and competition for binding sites with pathogens, but from 
competition for nutrients as well as the production of exogenous antimicrobial and immune-
stimulating compounds. Some studies do correlate adhesive capacity with immune response 
[129,130], but it is uncertain to what extent confounded factors may influence observed probiotic 
activity. Understanding the molecular mechanisms behind microbial adhesion in the gut could 
help determine the degree of probiotic functionality imparted by adhesion alone.  
The validity of the experimental models used in the measurement of probiotic adhesion 
may, however, be difficult to interpret. No standard model for in vitro adhesion exists so findings 
vary widely not only between strains and species, but between models as well [131]. The in vitro 
model determines the nature of adhesion sites in the system; some cell culture models will 
emphasize the measurement of direct host-microbe cellular contact, whereas mucus-secreting 
cultures or immobilized mucus models will emphasize mucus and muco-oligosaccharide 
interactions more than other models. As summarized in Table 1.4, there are advantages and 
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disadvantages to various types of in vitro adhesion models. It may therefore be important to 
study adhesion in vitro via different methods for a more thorough understanding of the 
interaction mechanisms most important to probiotic adhesion. 
1.5.1 Mucus Adhesion Models. 
The simplest method to measure the adhesion of bacterial strains to mucus is by 
immobilizing commercially available mucin. Mucin is bound to microtitre well plates, bacterial 
culture is bound to the mucin and strains are compared thereafter in any number of methods, 
qualitatively or quantitatively [91,132,133]. The use of mucin alone in adhesion assays allows 
for the targeting of interactions between bacteria and particular mucins known to be expressed in 
a given host locations. It also isolates microbe-mucus interactions from other interactions, such 
as host cell-microbe interactions, which may or may not be desirable. One drawback of this 
model is the complication of microbial hydrophobic properties with mucus-binding properties. 
The comparison of hydrophobic binding interactions of bacteria to untreated polycarbonate wells 
with mucus binding interactions in treated wells in one study [131] showed that hydrophobic 
binding interactions are not easily separable from mucus binding interactions. 
1.5.2 Cell Culture Models. 
Cultures of human intestinal cell lines are often presumed to better represent the 
environment in vivo because of the presence of actual tissue. The availability of a simple in vitro 
intestinal tissue model, as in the Caco-2 cell line, has provided valuable insight into cellular 
interaction mechanisms that would have been much more difficult to obtain with more complex 
in vitro techniques or in vivo. Caco-2 and HT29 cells, the two most commonly used intestinal 
cell lines, can be grown in culture to form a homogeneous polar monolayer of mature enterocytes 
resembling the tissue of the small intestine [134]. These models were developed primarily for the 
study of absorption and permeability in the small intestine and are derived from intestinal 
carcinomas, so they may or may not be accurate models for adhesion to healthy colonic tissue 
[135]. Several studies have compared the extent of Caco-2 cell binding by potential probiotic 
bacteria to adhesion in vivo with mixed results [136,137]. Regardless, these cell lines do not take 
into account the omnipresent mucus layer found in the healthy intestinal tract. The HT29 cell 
line, however, can be treated with methotrexate (MTX) to differentiate the cells into mucin-
secreting goblet cells [138,139]. The production of mucus by HT29-MTX cells increase adhesion 
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of bacterial cells relative to Caco-2 or HT29 cells alone [140,141], further supporting the 
importance of the presence of mucus to bacterial adhesion.  
The HT29-MTX line is composed primarily of goblet cells, which incorporates a mucus 
layer into the model, but it still does not accurately represent the enterocyte/goblet cell ratio of 
the gut epithelial layer. In response to this drawback, Caco-2/HT29-MTX co-cultures have been 
developed [145–147]. Unfortunately, HT29-MTX differentiated goblet cells express MUC5AC 
and MUC5B at a much greater rate than MUC2 [139], which could be a significant drawback 
when studying microbial adhesion to the colon, where MUC2 is prevalent. HT29 cells also 
differentiate in the presence of 5-fluorouracil (FU) to secrete MUC2 [142], and while this would 
emulate the colonic environment more closely, the HT29-FU model only seems to have been 
used in the study of pathogens thus far [139,140]. 
1.5.3 Whole Tissue Models. 
The disadvantage of many models is that they don’t take into account the presence of normal 
GI microbiota and the competitive exclusion that would take place in vivo between established 
commensal populations and exogenous microbes. For a more complete model of intestinal tissue in 
vitro, encompassing the mucus layer and epithelial tissue accurately, but also accounting for the 
presence of commensal microbiota, whole intestinal tissue fragments can be used [148,149]. 
Resected fragments of healthy colonic tissue may be difficult to obtain, but likely display 
characteristics closer to those probiotic bacteria would be expected to encounter in vivo than other 
models. Similarly, organ culture can be employed to maintain the viability and architecture of the 
tissue and has been used to assess adhesive properties of pathogens [150,151]. As of yet, it does not 
seem that organ culture has been used in the study of probiotic organisms; the expense of using organ 
culture is more easily justifiable with pathogenic organisms that could not otherwise be used in 
human models safely, unlike probiotic organisms. 
1.6 CONCLUSIONS 
As the field advances, discovery and selection of better probiotic organisms will become 
more sophisticated. Refinement of cell-culture techniques to better represent colonic 
environment could provide more accurate measures of adhesion, further aiding the selection of 
the best probiotic candidates for clinical trials. Printed glycan microarrays are beginning to be 
used to elaborate binding patterns of whole bacterial cells to different glycan structures [152]. 
Discoveries using similar techniques could promote the understanding of specific affinities for 
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different binding proteins. Determining the structural characteristics and binding specificities of 
mucus-binding proteins improve our understanding of the mechanisms behind probiotic-host 
interactions. This could in turn lead to the development of better tools to select the most 
beneficial probiotic organisms, potentially opening the door for designer probiotics engineered or 
selected for desired host-responses. Likewise, a better understanding of host glycosyl legislation 
in the context of bacterial binding specificity could result in the development of probiotics 
targeted for specific hosts or host tissue.  
Regardless of what future advances may come, knowledge of the limitations within the 
study of bacterial adhesion, as in any field, should help in the interpretation of current discovery 
as well as with the planning of further research. 
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1.9 TABLES AND FIGURES 
Table 1.1. Known Human MUC genes, their functions and locations. 
Gene 
Organisms with 
known homologues1 
Function2 
GeneAtlas 
Location of 
Highest 
Expression2: 
Type 
Selected 
References 
MUC1 
Dog, cow, mouse, 
rat, rabbit 
Cellular signal transduction, 
barrier activity 
Lungs Membrane [28,29] 
MUC2 
Chimpanzee, dog, 
chicken 
Primary extracellular matrix 
constituent in colon, lubricant 
activity 
Colon Secretory [25,28] 
MUC3A Rat, mouse 
Involved in epithelial cell 
protection, adhesion 
modulation, and signaling 
Various Membrane [30] 
MUC3B Rat, mouse 
Unknown, possibly cellular 
signal transduction 
Various Membrane [30] 
MUC4 
Many mammals, 
chicken, frog, 
platypus 
Involved in intestinal 
epithelial cell differentiation, 
renewal, lubrication 
Colon Membrane [31,32] 
MUC5B 
(MUC9) 
Chimpanzee, 
zebrafish, mouse, 
chicken, more 
Unknown, primarily lubricant Various Secretory [33,34] 
MUC5AC 
Chimpanzee, rat, 
zebrafish 
Major component of airway 
mucus involved in intestinal 
epithelial cell differentiation 
Trachea, 
Lungs 
Secretory [35,36] 
MUC6 
Chimpanzee, dog, 
mouse, chicken 
Unknown, involved in renal 
morphogenesis processes 
Pancreas, 
digestive and 
reproductive 
systems 
Secretory [36-38] 
MUC7 
Chimpanzee, cow, 
rat 
Facilitating the clearance of 
oral bacteria 
Salivary 
Gland 
Secretory [39,40] 
MUC8 Unknown Unknown Trachea Secretory [41] 
MUC12 
(MUC11) 
Cow, M.grisea, N. 
crassa, rice 
May be involved in epithelial 
cell regulation 
Colon Membrane [42] 
MUC13 
Chimpanzee, dog, 
mouse, rat 
Barrier function in epithelial 
tissues 
Pancreas, 
small 
intestine, 
colon 
Membrane [43] 
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Table 1.1. (cont.) 
Gene 
Organisms with 
known homologues1 
Function2 
GeneAtlas 
Location of 
Highest 
Expression2: 
Type 
Selected 
References 
EMCN 
(MUC14) 
Dog, cow, mouse, 
rat, chicken 
Interferes with the assembly 
of focal adhesion complexes 
Fetal lung, 
uterus, 
thyroid 
Membrane [44] 
MUC15 
Chimpanzee, cow, 
mouse, rat 
Barrier function in epithelial 
tissues 
Testis leydig 
cell 
Membrane [45] 
MUC16 
(CA125) 
Chimpanzee, dog, 
mouse, chicken 
Unknown, plays a role in 
ovarian cancer 
Lymph 
nodes, 
respiratory 
tract 
Membrane [46,47] 
MUC17 
(MUC3) 
Chimpanzee, S. 
pombe, S. cerevisiae, 
and K. lactis 
Extracellular matrix 
constituent, lubricant activity 
Small 
intestine, 
stomach 
Membrane [48,49] 
MCAM 
(MUC18, 
CD146) 
Chimpanzee, dog, 
mouse, rat, zebrafish 
AKA "melanoma cell 
adhesion molecule", cell-cell 
adhesion 
Various Membrane [50,51] 
MUC19 
Chimpanzee, dog, 
mouse, rat, frog 
Major gel-forming mucin in 
the human middle ear 
Secretory 
cells of the 
ears and eyes 
Secretory [52] 
MUC20 
Chimpanzee, dog, 
cow, mouse, rat 
Cellular signal transduction 
Intestines, 
respiratory 
and urinary 
tract 
Membrane [53] 
MUC21 
Chimpanzee, cow, 
mosquito, and A. 
thaliana 
Unknown, mediates cell 
adhesion 
Unknown Membrane [54,55] 
CD164 
(MUC24) 
Chimpanzee, dog, 
cow, mouse, rat, 
chicken, zebrafish 
Regulates stem cell 
localization to the bone 
marrow 
Thyroid, 
placenta, 
intestines, 
immune 
cells 
Membrane [56] 
1: via HomoloGene [57] database 
    
2: via GenAtlas [58] and BioGPS [59] databases 
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Table 1.2. Adhesion promoting proteins in Lactobacillus spp.  
Protein Info Species Refs 
MUB Demonstrates binding to mucus in vitro L. reuteri [87] 
MucBP Domain 
Containing Proteins 
Contain MucBP domains, implicated in mucus 
adhesion 
13 known 
Lactobacillus spp. 
[109] 
Pili Pilin subunit SpaC binds to mucus in vitro 
L. johnsonii,       
L. rhamnosus 
[91-93] 
32-Mmubp Demonstrates binding to mucus in vitro L. fermentum [99] 
SlpA 
Knockouts show diminished adhesion to mucus in 
vitro 
L. acidophilus [94] 
Msa Demonstrates binding of mannose in vitro L. plantarum [100] 
MapA Demonstrates binding to mucus in vitro L. reuteri [106,107] 
EF-Tu Expression upregulated in the presence of mucus L. johnsonii [101-105] 
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Table 1.3. MucBP domain containing sequences in available Lactobacillus genomes. 
Currently Available Whole Genomes Accession# Gene 
# of 
Domains 
Size 
Lactobacillus acidophilus NCFM   Q5FKK8 LBA0909 1 508aa 
  Q5FKA8 LBA1017 1 294aa 
  Q5FKA7 LBA1018 1 346aa 
  Q5FKA6 LBA1019 7 2650aa 
  Q5FKA5 LBA1020 5 2310aa 
  Q5FJS1 LBA1218 1 697aa 
  Q5FJC2 LBA1377 2 1017aa 
  Q5FJA7 LBA1392 17 4326aa 
  Q5FJ43 LBA1460 2 339aa 
  Q5FIQ0 LBA1609 2 643aa 
  Q5FIL0 LBA1652 3 1174aa 
  Q5FIF3 LBA1709 3 1208aa 
Lactobacillus brevis ATCC 367  Q03U29 LVIS_0122 2 912aa 
  Q03T21 LVIS_0493 3 1519aa 
  Q03P66 LVIS_1947 1 1111aa 
  Q03NB2 LVIS_2262 1 422aa 
Lactobacillus crispatus ST1  D5H0E1 LCRIS_00029 3 1232aa 
  D5H2Y1 LCRIS_00919 7 2935aa 
  D5GXR1 LCRIS_01123 1 304aa 
  D5GZ92 LCRIS_01654 2 3552aa 
Lactobacillus fermentum IFO 3956  B2GFA4 LAF_0157 1 208aa 
  B2GBH7 LAF_0673 2 1059aa 
Lactobacillus gasseri ATCC 33323  Q047B3 LGAS_0044 4 873aa 
  Q047B2 LGAS_0045 11 3692aa 
  Q047B1 LGAS_0046 4 985aa 
  Q046R7 LGAS_0143 6 2823aa 
  Q045Q7 LGAS_0410 5 2457aa 
  Q043P5 LGAS_0939 2 615aa 
  Q043P2 LGAS_0942 10 2833aa 
  Q043P0 LGAS_0944 1 524aa 
  Q041C4 LGAS_1655 2 1425aa 
  Q041B7 LGAS_1663 6 2449aa 
  Q041A9 LGAS_1671 4 2552aa 
  Q040V9 LGAS_1725 6 1993aa 
Lactobacillus helveticus DPC 4571  A8YTV1 lhv_0494 1 155aa 
  A8YTV2 lhv_0495 1 178aa 
  A8YUX0 lhv_0973 1 278aa 
  A8YUX3 lhv_0979 1 858aa 
Lactobacillus johnsonii FI9785  D0R4C3 FI9785_1070 6 3401aa 
  D0R5H6 FI9785_1482 5 1356aa 
Lactobacillus johnsonii NCC 533  Q74LY7 LJ_0046 4 870aa 
  Q74LY6 LJ_0047 6 2139aa 
  Q74LY5 LJ_0048 4 983aa 
  Q74L43 LJ_0382 4 3619aa 
  Q74KU3 LJ_0484 4 4037aa 
  Q74HP3 LJ_0574 5 1571aa 
  Q74HU0 LJ_0621 5 2789aa 
  Q74HW0 LJ_0641 3 1563aa 
  Q74HA8 LJ_1839 7 1814aa 
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Table 1.3. (cont.) 
Currently Available Whole Genomes Accession# Gene 
# of 
Domains 
Size 
Lactobacillus plantarum JDM1  C6VP10 JDM1_1038 4 1082aa 
  C6VQ03 JDM1_1381 6 2219aa 
  C6VKM3 JDM1_2438 4 1345aa 
  C6VL52 JDM1_2491 4 2037aa 
  C6VL55 JDM1_2494 1 750aa 
Lactobacillus plantarum WCFS1  Q88Y49 lp_0946 1 1189aa 
  Q88XH5 lp_1229 3 1010aa 
  Q88WI9 lp_1643 6 2219aa 
  Q88UJ0 lp_2486 2 917aa 
  Q88TB8 lp_3059 4 1356aa 
  Q88T70 lp_3114 4 2032aa 
  Q88T67 lp_3117 1 750aa 
Lactobacillus reuteri DSM 20016  A5VKZ1 Lreu_1258 1 745aa 
Lactobacillus reuteri JCM 1112  B2G8C6 LAR_1192 1 745aa 
Lactobacillus salivarius CECT 5713  D8IM74 HN6_01114 4 785aa 
Lactobacillus salivarius UCC118  Q1WSI9 LSL_1335 4 785aa 
Data gathered from the Pfam [110] and Uniprot [111] databases. 
Databases contained no MucBP domain containing sequences in Lactobacillus delbrueckii subsp. 
bulgaricus strains ATCC 11842 and ATCC BAA-365, Lactobacillus fermentum CECT 5716, 
Lactobacillus casei strains Zhang, BL23, and ATCC334, Lactobacillus plantarum subsp. plantarum ST-
III, Lactobacillus rhamnosus strains GG and Lc 705, and Lactobacillus sakei subsp. sakei 23K . 
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Table 1.4. Summary of in vitro adhesion models 
Model Description Advantages Disadvantages References 
Immobilized 
Mucus 
Mucus preparations 
immobilized, usually in 
microtitre wells 
Fast, isolates mucus-
microbe interactions from 
other in vivo conditions 
Difficult to separate 
mucus-specific  from 
hydrophobic interactions 
[84,124-
126] 
Cell Culture 
Polar monolayer of 
enterocytes resembling 
intestinal tissue 
Provides conditions more 
similar to in vivo 
environment 
Derived from cancer 
cells, could differ from 
healthy tissue  
Caco-
2/HT29 
Caco-2 and HT29 
carcinoma cell lines 
Simple, well established in 
literature 
Does not account for 
mucus presence 
[127-130] 
HT29-
MTX/FU 
HT29 culture treated 
with methotrexate or 
fluoruracil to secret 
mucus of different 
types 
Accounts for presence of 
mucus 
Not representative of 
cell-type ratios in 
mucosal epithelial 
tissues 
[131-134, 
138-140] 
Co-cultures 
Mixed culture of 
secreting and mucus-
secreting cells 
Better represents cell-type 
ratio of mucosal epithelial 
tissues 
Little literature for use in 
adhesion studies 
[135-137] 
Whole 
Tissue 
Whole, intact or 
excised tissue 
Provides in vitro 
conditions most similar to 
in vivo environment 
Costly, difficult to obtain 
 
Resected 
tissue 
Fragments of tissue 
excised from host 
Mucus, epithelial tissue, 
and commensal organisms 
accounted for in model 
Only small fragments at 
a time available from 
living hosts 
[141,142] 
Organ 
culture 
Whole organs 
maintained in vitro 
Better maintains the 
architecture of the tissue 
Prohibitively expensive, 
may not function in same 
manner as in vivo 
[143,144] 
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Figure 1.1. Diagram of the MUC2 protein core. The protein termini contain cysteine-rich regions 
homologous to von Willebrand Factor (vWF) domains (a); The N-terminal regions of MUC2 proteins 
contain vWF domain homologs D1, D2, D′, and D3 and the C-terminal regions contain vWF domain 
homologs D4, B, C, and CK. These terminal domains are responsible for the extensive 
polymerization between mucin monomers, along with the cysteine rich interruptions between 
glycosylated tandem repeats (b); The first of two repetitive domains (c) contains 21 repeats of an 
irregular motif, whereas the second domain (d) is formed of 50–115 tandem 23aa motifs 
(PTTTPITTTTTVTPTPTPTGTQT). Threonines in the repeats are O-glycosylated, forming a densely 
packed envelope of short, branched carbohydrate chains surrounding these regions. 
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Figure 1.2. Simplified histological cross-section of microbial adhesion to the colonic mucosal surface at various magnifications. (a) The 
layer of mucus atop colonic epithelial villi. Goblet cells can be seen interspersed throughout the columnar enterocytes, producing secretory 
mucin that makes up the gel matrix. The microbial communities residing in and on top of the mucus layer can only be found at substantial 
concentrations in the outermost regions of the mucus; (b) The mucus-bacteria interface. The mucin molecules polymerize to form the 
mucus layer matrix to which cells adhere. Extensive disulfide bonding between cysteine-rich regions of the mucin protein cores creates the 
characteristic viscoelastic properties of mucus. Oligosaccharide modifications of mucin protein cores form ―bottle-brush‖ regions providing 
substrate for adhesion to binding proteins on bacterial cell surfaces; (c) A proposed molecular mechanism of adhesion. Evidence suggests 
that putative mucin-binding proteins anchored to the bacterial cell wall may interact with the glycosyl modifications of the mucin proteins to 
promote adhesion of the cell to the mucus layer. Mucin oligosaccharide structures vary due to tissue and cell-specific glycosyltransferase 
expression levels, so the specificity of particular oligosaccharide moieties may lead to preferential binding of particular bacteria to different 
host niches. 
32 
 
CHAPTER 2: GLYCAN-SPECIFIC WHOLE CELL AFFINITY CHROMATOGRAPHY: 
A VERSATILE MICROBIAL ADHESION PLATFORM2 
2.1 ABSTRACT 
We have sought a universal platform for elucidating and exploiting specificity of glycan-
mediated adhesion by potentially uncharacterized microorganisms. Several techniques exist to 
explore microbial interactions with carbohydrate structures. Many are unsuitable for 
investigating specific mechanisms or uncharacterized organisms, requiring pure cultures, 
labeling techniques, expensive equipment, or other limitations such as questionable stability, 
stereospecificity, or scalability. We have adapted an affinity chromatography resin as a model to 
overcome these drawbacks, among others. It readily allows for the quantification, selection, and 
manipulation of target organisms based on interactions with glycan ligands. To maximize its 
utility as a selective screening method, we have constructed the tool such that it: 
 Promotes whole-cell interactions using viable, unaltered cells. 
 Provides robust spatial interactions with target glycans, presented with controlled stereo-
specificity, for high affinity/avidity interactions that reflect a complex in vivo matrix. 
 Has the ability to utilize any reducing glycan, is quick, efficient, safe, and affordable to 
construct, and is scalable and reusable for multiple applications.  
2.2 METHOD DETAILS PART 1: FORMATION OF C-GLYCOSIDE KETONES AND 
THEIR IMMOBILIZATION 
In brief, the affinity chromatography model construction consists of derivatizing a target 
glycan with a ketone modification at the reducing end to facilitate covalent attachment to a 
hydrazide-functionalized resin. Quantitative conversion of a glycan to its C-glycoside ketone 
derivative can be accomplished as described previously [1] via a straightforward, one-pot 
reaction requiring no activating or protecting groups. Ketone derivatization makes the glycoside 
highly reactive toward hydrazines, facilitating rapid immobilization onto hydrazide-modified 
chromatographic resin. Furthermore, formation of a C-glycoside ketone derivative ensures a 
stereospecific modification that maintains the ring integrity of the glycoside, which may be 
                                                 
2 This chapter appeared in its entirety in the journal MethodsX: Van Tassell M.L., Price N.P., Miller M.J., 2014. 
Glycan-specific whole cell affinity chromatography: a versatile microbial adhesion platform. MethodsX 1(1), 244-
250. It is available open-access online at http://www.sciencedirect.com and using DOI: 10.1016/j.mex.2014.10.005. 
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essential for proper presentation to cell adhesins. For more information on the derivatization 
chemistry, see [2]. 
The resulting C-glycoside ketohydrazide resin could be constructed with any 
carbohydrate with an aldose residue at its reducing end. The reactions detailed below are scalable 
as long as the molar ratio of the components is equivalent; we have successfully derivatized over 
5 mmol of carbohydrate and made batches of resin up to 5 mL. While we have found that the 
specified hydrazide-functionalized resin works well, any other hydrazide-functional substrate 
should also work, but may require an altered ratio of C-glycoside ketone. 
2.2.1 Materials. 
 Glycan(s) of interest 
 Sodium bicarbonate buffer: 38 g L−1 NaHCO3, pH 8.5 
 Acetyl acetone 
 Ethyl acetate 
 Dowex 50WX8 strong acid ion exchange resin (Sigma–Aldrich, cat. 217492) 
 Ultralink hydrazide resin (Thermo Scientific, cat. 53149) 
 Pyridine 
 Sodium azide 
Note: Materials lists include only non-standard items. Common laboratory ware and 
equipment such as water baths are assumed to be available. 
2.2.2 Procedure. 
A1. In a glass screw-cap tube, dissolve 0.3 mmol of a desired glycan in 1 mL of sodium 
bicarbonate buffer.  
A2. Add 35mL of acetyl acetone (approx. 1.1:1 molar ratio with glycan) and vortex to 
dissolve.  
A3. Incubate sealed glass tube in a water bath or heating block at 80–90 8C for at least 4 h.  
A4. Remove tube and cool to ambient temperature. A slight yellow-brown discoloration may 
develop, particularly with larger or more complex glycans.  
a. A small amount of pressure from CO2 release may build within the tube during 
incubation. Vent the tube slowly prior to opening and it should not be problematic.  
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A5. Add 3 mL of ethyl acetate and shake to mix. Allow ethyl acetate to separate from the 
aqueous phase and discard this upper layer.  
a. If the ethyl acetate is slow to separate, place the reaction in a freezer for 10–15 min to 
help.  
A6. Add acid ion exchange resin to the aqueous phase, 10–20 mg at a time in order to 
neutralize. Shake gently to release CO2 and add more resin until no more gas is 
generated.  
A7. Remove the aqueous phase, containing the newly formed C-glycoside ketone, from the 
ion exchange resin and retain.  
A8. C-glycoside ketone formation may be verified by mass spectrometry at this stage if 
desired.  
A9. A8 Prepare 1 mL (bed volume) of hydrazide resin in a glass vial and wash with water to 
remove storage buffer.  
A10. Remove excess water from the resin and apply 200mL of the C-glycoside ketone 
solution.  
A11. Evaporate the majority of the aqueous phase from the resin under an air stream, carefully 
so as to not displace the resin from the vial. 
a. Dilute the resin in 2 mL pyridine, vortex to mix, and incubate at ambient temperature 
for at least 1 h.  
A12. Carefully remove pyridine with a Pasteur pipette and wash the resin in 3–4 volumes of 
water. Wash 5–6 times to remove all pyridine.  
A13. Retain the resin for use or suspend in 0.02% sodium azide for 4 8C storage. We have 
found that the resin remains functional for longer than two months. 
2.3 METHOD DETAILS PART 2: C-GLYCOSIDE RESIN VERIFICATION 
Once the above procedure has been completed, validation that the target glycan has been 
immobilized may be desired. We have found that if the glycan is a disaccharide or larger, 
glycosidic linkages can be acid-hydrolyzed to release constituent monomers for analysis, by 
mass-spectrometry for example, as described below. The ketone-modified monosaccharide from 
the reducing terminus of the glycan, which has been immobilized to the hydrazide resin, is not 
released by acid hydrolysis (Fig. 2.1A); it should be the sole component not detected by further 
analysis such as mass-spectrometry (see [3] and [4] for more on analytical methods). 
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Alternatively, a lectin-affinity assay can be performed to confirm immobilization of 
glycans. This is particularly useful for immobilized monosaccharides, which are not readily acid-
hydrolysable. It can also verify structural conformation of the carbohydrate presented on the 
resin, however it may require optimization for each application. Lectins with appropriate 
specificities for target glycan components must be used. Similarly, the lectin load may vary 
depending on label and a compatible buffer, as suggested by the supplier, must be used to ensure 
effective adhesion of the lectin. For example, we have used Concanavalin A to validate the 
successful immobilization of alpha-d-mannose (see Fig. 2.1B). 
2.3.1 Materials. 
 C-glycoside ketohydrazide resin, as prepared above in Part 1 
 2 N Trifluoroacetic acid (TFA) 
 Hydroxylamine HCl, saturated solution in pyridine 
 Acetic anhydride 
 Ethyl acetate for extractions 
 Stoppered spin columns with 30 μm pore filters (Thermo Scientific, cat. 69725) 
 Fluorescently labeled lectin(s) specific for target glycan 
o e.g. Fluorescein labeled Concanavalin A (Vector Labs) 
 Lectin buffer compatible with desired lectin (see suppliers’ recommendations) 
o e.g. 10 mM HEPES, 0.15 M NaCl, 0.1 mM CaCl2, pH 7.5 
 Fluorescence microplate reader and compatible 96-well fluorescence microplates 
2.3.2 Procedure – Hydrolysis and Mass Spectrometry. 
A1. 150 μL of resin was placed in a glass vial with 0.5 mL of 2 N TFA and hydrolyzed on a 
heating block at 120 °C for 30 min. This was then evaporated to dryness on an airline. 
A2. 0.5 mL saturated hydroxylamine HCl in pyridine was added to the dried residue and 
incubated for another 20 min at 60 °C.  
A3. 0.5 mL acetic anhydride was added and reacted for another 20 min at 60 °C, to form 
aldononitrile acetate derivatives. The reaction was evaporated (fume hood), re-dissolved 
in ethyl acetate, and back extracted with water. The upper, ethyl acetate layer was 
removed and analyzed by GC/MS as described [5]. 
2.3.3 Procedure – Affinity Chromatography with Lectins. 
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B1. 100 μL (bed volume) of mannose-C-glycoside resin was placed in a stoppered 1 mL spin 
column and equilibrated by washing with 0.5 mL lectin buffer three times. 
B2. The resin was incubated in the dark for 10 min at ambient temperature with 200 μL of 
lectin buffer containing 10 μg fluorescein-conjugated lectin. 
B3. The column was un-stoppered and unbound lectin was allowed to wash out via gravity, 
generally over 2–5 min. 
B4. This flow-through was collected along with three 200 μL washes with lectin buffer and 
three 200 μL elutions with lectin buffer containing 200 mM mannose. 
a. The fluorescent intensity of each sample was measured in a microplate via FLx800 
Fluorescence Microplate Reader (BioTek) to compare retention and elution of labeled 
lectins. 
B5. Fluorescence signal in elution samples that is in excess of the last washes is indicative of 
binding by the lectin and its subsequent release. 
2.4 METHOD DETAILS PART 3: BACTERIAL GLYCAN-AFFINITY 
CHROMATOGRAPHY 
This C-glycoside resin allows for isolation of bacterial glycan affinity from otherwise 
complex mixtures while quantifying and manipulating interactions with specific target glycans. 
This has broad application for assessing glycan affinity, specificity, and mechanisms of 
displacement or competition. As numerous studies of glycan-mediated detection methods focus 
on the well-characterized interaction of Escherichia coli type-I fimbriae with mannosides, we 
have validated our platform with immobilized alpha-D-mannose and a non-pathogenic laboratory 
strain of E. coli. 
Fig. 2.2A demonstrates the retention of E. coli K12 to mannose resin that is inhibited 
only by mannose-containing competitors. Bound cells could also be recovered for enumeration 
by elution with competing glycans, by altered pH, or denaturants, but we have found that the 
discrepancy between cell load of the inocula and the flow-through is more consistent and is 
sufficient for an accurate picture of initial retention.  
Since the resin can be as easily constructed with any reducing carbohydrate, and no 
further modification of samples may be required, there is considerable potential for exploring 
alternative affinities of known and unknown organisms. To this end, we have also established 
that the resin is compatible with adhesion by less tractable organisms than E. coli to more 
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complex glycan structures. Fig. 2.2B demonstrates the retention of Campylobacter jejuni NCTC 
11168 to immobilized 2′fucosyllactose (2FL) in a carbohydrate specific manner, a specificity 
that has been demonstrated to a lesser extent on Caco-2 cell culture [6]. 
The same principles of glycan adhesion specificity can be applied as a selective screening 
tool for separating cells with differing affinity. A selective pressure for the adhesive affinity to 
target glycans could be beneficial to the exploration competitive exclusion or the directed 
evolution of high-affinity strains. The example we have used to demonstrate this feature reflects 
the phase-variation of the E. coli fimbrial operon. Cells that are fimbriated result in a colony 
morphology differentiable from those that are non-fimbriated [7], which can be verified by PCR 
amplification and digestion of the fim switch [8]. 
Fig. 2.3 demonstrates the selective pressure of immobilized C-mannoside resin for the 
separation of E. coli K12 mixed phenotypes. On average, approximately 94–96% of fimbriated 
cells in a given population could be retained on the resin, while only 15–20% of non-fimbriated 
cells would remain, after the initial flow-through alone (data not shown). Phase-variability of the 
populations derived from fimbriated and non-fimbriated colonies may account for the deviation 
from these numbers that is seen in Fig. 2.3A, as even inocula prepared from fimbriated colonies 
were partially non-fimbriated (Fig. 2.3B). 
2.4.1 Materials. 
 Mannose-C-glycoside and 2FL-C-glycoside ketohydrazide resins, as prepared above in 
Part 1 
 Stoppered spin columns with 30 μm pore filters (Thermo Scientific cat. 69725) 
 E. coli ATCC 29425 (K12) 
 C. jejuni NCTC 11168 (Cj11168) 
 Brain-Heart Infusion broth and agar plates (BHI; BD cat. 237500) 
 Mueller Hinton broth (BD cat. 275710) 
 Citrated bovine blood (Quad Five cat. 930) 
 Phosphate buffered saline (PBS) 
 Mannose 
 Galactose 
 Mannan from Saccharomyces cerevisiae (Sigma cat. M7504) 
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 Lactose 
 2′Fucosyllactose 
2.4.2 Procedure – Determining Specificity of Microbial Adhesion. 
A1. Prepare bacterial cultures grown to mid-late exponential growth phase. 
a. Escherichia coli K12 was grown aerobically in BHI at 37 °C with 200 RPM shaking 
to an optical density at 600 nm (OD600) of 0.8–1.0. 
b. C. jejuni 11168 was grown under microaerophilic conditions as a lawn on Mueller 
Hinton-based blood agar plates with 5% bovine blood (MHB) at 37 °C for 24 h. 
A2. Prepare columns as before for lectin affinity verification, instead washing three times 
with 0.5 mL PBS to equilibrate prior to each test. 
a. Optional: non-specific binding can be pre-blocked with the addition of protein such as 
bovine serum albumin, but we have found this to be unnecessary for our bacterial 
samples. 
A3. Harvest bacterial cells to prepare dilutions for application to the column. 
a. K12 culture was centrifuged at 3000 × g for 3 min then re-suspended in PBS to wash, 
repeating twice. 
b. Cj11168 culture was removed from MHB by a sterile inoculating loop and suspended 
in PBS with brief vortexing. Culture was centrifuged at 3000 × g for 5 min then re-
suspended in PBS to wash, repeating twice. 
A4. Prepare the inocula for the columns by diluting the washed bacterial cultures in PBS to 
obtain approximately 2 × 105 CFU/mL. 
a. K12 and Cj11168 were standardized to an OD600 of 0.50 ± 0.01, resulting in 
approximately 4 × 108 CFU/mL, which was then diluted accordingly. 
A5. Immediately prior to application to the columns, combine 0.5 mL aliquots of inocula with 
test competitors of interest. 
a. K12 inocula were combined with either 100 mM mannose, 100 mM galactose, 
40 mg/mL yeast mannan, or PBS as a control. 
b. Cj11168 inocula were combined with 10 mg/mL 2FL, 10 mg/mL lactose, or PBS as a 
control. 
A6. Add the inocula to the columns and allow incubation until the resin settles, approximately 
3 min. 
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A7. Open the columns and allow inocula to wash out via gravity until run dry, generally about 
5 min. 
A8. Collect the flow-through, plate on appropriate agar medium for overnight incubation, and 
enumerate to determine the amount of cells that were not retained in the column. 
A9. Plate the inocula for enumeration on appropriate agar medium in parallel. 
A10. Calculate bacterial retention as the fraction of the cells from the inoculum not recovered 
in the flow-through. 
2.4.3 Procedure – Screening Microbial Populations by Glycan Affinity. 
B1. Escherichia coli K12 was grown aerobically overnight on BHI agar at 37 °C. 
B2. Colonies of fimbriated and non-fimbriated K12 were re-suspended in BHI broth to 
approximately OD600 0.3. 
B3. Culture was incubated until grown past OD600 0.50, and then washed in PBS and 
standardized as above. 
B4. Columns and bacterial dilutions were prepared as above and affinity assay was performed 
as before, but without combination of competing sugars. 
B5. Enumeration of inocula and assayed samples included counting the colonies of fimbriated 
and non-fimbriated cells separately to assess their proportions. 
Note: We have found that C-glycoside resin can be reused in multiple successive bacterial 
adhesion assays with no detectable decrease in effectiveness following washes with free 
competing ligand, detergent, heat, or other protein denaturants. 
2.5 ADDITIONAL INFORMATION 
A number of tools have been demonstrated for investigating mechanisms of microbial 
glycan adhesion, including tissue culture [6] and [9], glycan microarrays [10] and [11], and other 
forms of chromatography [12] and [13]. As discovery platforms, however, many current 
techniques for exploiting glycan-mediated adhesion are not suitable for certain avenues of 
investigation. Microarrays require very low quantities of target ligand, but frequently have 
difficulty elaborating whole-cell interactions. For example, of whole-cell bacterial samples 
applied to glycan arrays from the Consortium for Functional Glycomics [14] the majority of 
results are inconclusive. Many arrays instead rely on the use of cell extracts and purified 
proteins. This often requires prior knowledge of expected interactions, including specific 
adhesive proteins or known adherent organisms and the optimal conditions for their growth and 
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manipulation. Even when whole-cell adhesion is achievable, many methods do not facilitate 
further manipulation of the organisms. Such formats are not easily scalable or practical for 
enrichment in situ. 
Models of in vitro tissue culture intent on elaborating glycan-mediated bacterial adhesion 
reflect in vivo conditions more closely, but cannot generally account for the presence of 
numerous other variables inherent to the cellular milieu and do not isolate specific glycan 
moieties that may be of interest [15]. Additionally, many tools require manipulation of 
organisms prior to use for proper detection, including most array and glycoparticle models. 
Alterations such as fluorescent staining or radiolabeling may have undetected consequences 
regarding adhesion or viability, but these effects are often ignored. Furthermore, many of these 
techniques also rely on complex, difficult, or hazardous chemical reactions for derivatization and 
immobilization of glycans that may not guarantee proper stereospecificity. 
C-glycoside affinity resin is simple to construct and use, versatile, and sidesteps 
numerous pitfalls prevalent in methods of similar approach to glycan-bacteria adhesion. 
Optimization of the model for the affinity-based selection of probiotic organisms and the 
investigation of multiple glycan-pathogen interactions is currently underway, which is expected 
to facilitate the discovery and application of probiotic mechanisms for the prevention of 
pathogenic adhesion. 
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Figure 2.0. Graphical Abstract 
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Figure 2.1. Example methods for analysis of C-glycoside ketone immobilization. (A) Acid 
hydrolysis of the glycosidic bonds within the immobilized glycan releases component 
monomers, except for the ketone-modified terminal residue bound to the hydrazide resin. 
Immobilization of the C-glycoside ketone could be verified by examining the hydrolysate via 
various analytical means, including HPLC, enzymatic assay, or mass-spectrometry. (B) 
Attachment of a lectin or set of lectins of known specificity compatible with the target glycan 
can also verify its immobilization. Elution of the lectin via ligand competition demonstrates that 
the lectin was adherent in a glycan-specific fashion, indicating the glycan was immobilized with 
a structurally compatible presentation. 
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Figure 2.2. Retention of E. coli K12 on mannose affinity chromatography resin in the presence 
of soluble competitors, standardized as a fraction of the inoculum. (A) E. coli K12 adhesion to 
mannose-C-glycoside resin was inhibited only in the presence of soluble competitive mannosyl 
structures. (B) Campylobacter jejuni 11168 adhesion to 2FL-C-glycoside resin was inhibited 
only by the presence of soluble 2FL. PBS: phosphate buffered saline non-competitive control, 
MAN: mannose (50 mM) competition, GAL: galactose (50 mM) competition, YM: yeast 
mannan (20 mg/mL) competition, 2FL: 2’fucosyllactose (5 mg/mL) competition, LAC: lactose 
(5 mg/mL) competition. Data shown are averages ± standard error, experiments performed in 
triplicate. 
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Fig. 2.3. Retention of E. coli K12 on mannose affinity chromatography resin differs based on 
fimbriation of the inocula. (A) Inocula composed of fimbriated cells (Fim +) was recovered at a 
significantly lower level than non-fimbriated cells (Fim -), indicating they had a greater affinity 
for the resin. (B) Of the cells from a predominantly fimbriated inoculum (Inoc), the initial wash-
through (Wash) shows a distinct enrichment of non-fimbriated cells. This demonstrates the 
resin’s potential for separating populations based on selection for glycan adhesion. Data shown 
are averages ± standard error, experiments performed in triplicate. 
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CHAPTER 3: USE OF A MINIATURE LABORATORY FRESH CHEESE MODEL FOR 
INVESTIGATING ANTIMICROBIAL ACTIVITIES3 
3.1 ABSTRACT 
Hispanic-style fresh cheeses, such as queso fresco, have relatively low salt content, high 
water activity, and near neutral pH, which predisposes them to the growth of Listeria 
monocytogenes. Biosafety constraints limit the incorporation of L. monocytogenes into cheeses 
manufactured via traditional methods in challenge studies, so few have focused on in situ testing 
of novel antimicrobials in fresh cheeses. We have developed a modular, miniaturized laboratory-
scale queso fresco model for testing the incorporation of novel antilisterials. Here we have 
demonstrated the assessment of the antilisterials nisin and ferulic acid, alone and in combination, 
at various levels. Our results support the inhibitory effects of ferulic acid in cheese, against both 
L. monocytogenes and its common surrogate Listeria innocua, and we provide preliminary 
evaluation of its consumer acceptability. 
3.2 INTRODUCTION 
Most styles of cheese are not commonly associated with foodborne pathogens. 
Exceptions generally include soft-ripened, unripened, and raw-milk or improperly pasteurized 
cheeses, which have been associated with the majority of outbreaks in cheeses. Most of the risk 
associated with cheeses in general is due to outbreaks of Listeria monocytogenes in Hispanic-
style fresh cheeses such as queso fresco (Batz et al., 2011). Such non-cultured, unripened cheeses 
have high moisture content, low salt content, and near neutral pH, so proper refrigeration is 
required to maintain shelf life. However, L. monocytogenes can proliferate at refrigeration 
temperatures, leaving few hurdles for its inhibition.  
Recent multi-state outbreaks of listeriosis highlight ongoing concerns regarding 
contamination of Hispanic-style fresh cheeses (Centers for Disease Control and Prevention, 
2014a,b). Outbreaks from illicitly produced queso fresco make headlines (MacDonald et al., 
2005) and emphasize that a growing demand for fresh cheeses is outpacing the supply by current 
markets, because many manufacturers hesitate to capitalize on such demand due to liability 
concerns. Strategies are needed to help prevent Listeria outbreaks and allow for safer expansion 
                                                 
3 This chapter appeared in its entirety in Journal of Dairy Science: Van Tassell M.L., Ibarra-Sanchez L.A., Takhar 
S.R., Amaya-Llano S., Miller M.J., 2015. Use of A Miniature Laboratory Fresh Cheese Model for Investigating 
Antimicrobial Activities. J. Dairy Sci. 98(12), 8515-24. This article is reprinted with the permission of the publisher 
and is available online at http://www.sciencedirect.com/ and using DOI: 10.3168/jds.2015-9967. 
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of the market for Hispanic-style fresh cheeses. Outbreaks continue to occur, despite 
pasteurization of raw ingredients, due to listerial contamination during manufacturing processes. 
What research is available on Listeria control measures in fresh cheeses has confirmed survival 
and growth of L. monocytogenes during manufacturing as well as during storage under 
refrigeration (Leggett et al., 2012). Considering post-manufacture processes such as high-
pressure or additional heat treatment can unacceptably alter the delicate cheese structure (Hnosko 
et al., 2012), there are limited measures available to eliminate post-pasteurization contamination. 
This suggests that direct incorporation of antimicrobial compounds into fresh cheeses may be 
necessary for Listeria control.  
A wide variety of plant essential oils, extracts, and their derivatives (Smith-Palmer et al., 
1998; Lis-Balchin and Deans, 1997), as well as organic acids (Shin et al., 2007; Silva et al., 
2012), have been shown to exhibit antilisterial activity in vitro, but few have been incorporated 
into a fresh cheese challenged with pathogens. This may in part be due to the potential impact of 
such additives on the subtle flavor of fresh cheeses, but the lack of a convenient laboratory-scale 
fresh cheese-manufacturing model for use in pathogen challenge studies may also present a 
hurdle to the investigation of novel antimicrobials. In the manufacturing processes of 
commercial cheese, antimicrobial compounds may be incorporated into the pasteurized milk or 
the curd to inhibit listerial growth, because listerial contamination could occur at many points 
throughout the production process. Listeria could be present from the raw or insufficiently 
pasteurized milk or be introduced at various later stages including coagulation, curd cutting, 
draining, transfer, and packaging (Silva et al., 2003). However, most studies of antilisterial 
compounds in fresh cheese obtain retail products to which Listeria and the treatments are then 
surface-applied (Soni et al., 2010; Malheiros et al., 2012; Silva et al., 2012; Soni et al., 2012). 
The use of a convenient and accurate small-scale model for production of fresh cheeses could 
allow for higher-throughput screening of novel additives than in pilot-scale manufacturing, 
which is cumbersome and impractical in most settings. Consequently, a small-scale model would 
be both more economical and more amenable to biocontainment during work with pathogens.  
Nisin exhibits broad-spectrum inhibition of Gram-positive organisms, including L. 
monocytogenes. It is the most commonly used bacteriocin in the food industry, often used in 
processed cheeses to inhibit spore germination. As with many bacteriocins, however, nisin has 
limited stability and efficacy in neutral pH environments (Delves-Broughton et al., 1996). 
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Several novel antimicrobial additives have been explored as alternatives. For example, ferulic 
acid is a hydroxycinnamic acid that has been investigated for its antioxidant properties, but has 
also been shown capable of inhibiting the growth of L. monocytogenes in ready-to-eat foods 
(Takahashi et al., 2013). While nisin alone may not be sufficient to mitigate the risk of L. 
monocytogenes in conditions of relative instability, its combination with other antimicrobial 
compounds may result in synergies that ultimately lead to products safe from listerial 
contamination. However, investigation within a model that appropriately reflects the food of 
interest would be necessary to effectively screen for novel antimicrobials and their combinations. 
The objective of this study was to develop a flexible, small-scale fresh cheese that 
accurately reflects the composition of commercial preparations and demonstrate its use to 
explore methods for prevention of microbial growth. Such a cheese-preparation model would 
ideally be contained entirely within a biosafety cabinet for investigation of antimicrobial impacts 
on pathogens and flexibly model different microbial contamination and intervention scenarios. In 
this study, we demonstrate applications of such a miniaturized laboratory queso fresco (MLQF) 
and explore methods for prevention of listerial growth in fresh cheese. We specifically 
investigate the in situ dose response of the common food-grade bacteriocin nisin and assess the 
impact of a novel antilisterial, ferulic acid, on Listeria innocua and L. monocytogenes in fresh 
cheese. 
3.3 MATERIALS AND METHODS 
3.3.1 Microorganisms and Culture Conditions. 
Listeria strains (Table 3.1) were recovered from frozen glycerol stock (-20ºC) by 
subculturing twice in brain heart infusion (BHI; Difco, Becton Dickinson and Co.) broth. 
Cultures were incubated for 24 h at 37°C with 200 rpm agitation. Enumeration of cultures was 
carried out on Listeria Oxford Agar (Difco) supplemented with 20 µg/mL ceftazidime (Tokyo 
Chemical Industry Co., Ltd.), incubated for 24-48 h at 37°C.  
3.3.2 Minimum Inhibitory Concentrations. 
Minimum inhibitory concentrations (MICs) for antimicrobials were tested via the broth 
microdilution method as described by Patel et al. (2011), with minor modification. Overnight 
cultures of Listeria were inoculated at approximately 105 CFU/mL into 96-well microtiter plates 
containing wells with serial 2-fold dilutions of nisin, in the form of Nisaplin (Danisco, New 
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Century, KS), or ferulic acid (Sigma-Aldrich, St. Louis, MOer) in BHI broth, starting from 5 
mg/mL or 10 mg/mL respectively. Plates were prepared in triplicate and the MIC for each was 
recorded as the lowest concentration that visibly prevented growth after overnight incubation at 
37ºC. 
3.3.3 Traditional-scale Queso Fresco Production. 
Pasteurized whole milk was warmed in stainless-steel, steam-jacketed cheese vats to 
35°C in batches of 20 L and 4g CaCl2 was added to promote firm curd formation. 3 mL of 
commercial bovine rennet was added to the milk after 1:10 dilution in deionized water. The curd 
formed over 45 min and was then cut into small cubes. The curds were stirred slowly and cooked 
for 30 min, increasing 1°C every 6 min until reaching 40°C. Two-thirds of the total whey was 
drained and 160 g NaCl was added to the curds and stirred for 10 min at 40°C. Residual whey 
was drained and the curds were transferred to cheese molds, then stored at 4°C. 
3.3.4 Miniature Laboratory Queso Fresco Production. 
Pasteurized whole milk was warmed to 35°C in batches of 50 mL. The milk was 
combined with 67 µL 0.75 g/mL CaCl2 and 15 µL of commercial rennet diluted to 1 mL in 
deionized water. The milk was divided into twenty five 2 mL portions in 2 mL micro-centrifuge 
tubes, which were then incubated at 35°C for 45 min in a water bath. The curds were then cut via 
several vertical strokes, at regularly alternating angles, with a sterile inoculating needle featuring 
a tip bent to conform to the bottom of the microcentrifuge tube. After cutting, curds were 
returned to the water bath and warmed for another 30 min, increasing 1°C every 6 min until 
reaching 40°C. Tubes were centrifuged at 6000 × g for 15 s then 100 µL of whey was removed 
from each tube and replaced with 100 µL 0.16 g/mL NaCl. The curds were stirred gently with a 
micropipette tip and returned to the water bath for an additional 20 min incubation at 40°C. The 
tubes were then centrifuged at 6000 × g for 10 min and whey was completely removed. Cheeses 
were then stored at 4ºC until further analysis. 
3.3.5 Dose-response of Nisin in MLQF. 
Two independent batches of queso fresco were prepared as described above with 3.15 
mg/mL, 6.25 mg/mL, 25 mg/mL, 31.25 mg /mL, 50 mg/mL and 100 mg/mL Nisaplin added into 
the milk prior to renneting. This corresponded to approximately 12.5 to 400 µg of nisin per g of 
cheese, based on the nisin content of Nisaplin. After salting the curd, 200 µL of whey was 
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removed from each tube and 200 µL of overnight culture of L. innocua was added, for a final 
concentration of approximately 105 CFU/g. The tubes were left at room temperature for 15 
minutes to allow bacterial attachment prior to pressing the curd via centrifugation. Cheeses were 
sampled after storage at 4°C for 0, 3, 6 and 28 days. At each time-point, two cheeses from each 
batch were sampled by mixing into 1:10 dilutions (w/v) of phosphate buffered saline using a 
pipet tip and then vortexing to further disrupt curd structure. Suspensions were then serially 
diluted for enumeration and spread-plated in triplicate on Listeria Oxford Agar supplemented 
with 20 µg/mL ceftazidime. Plates were incubated at 37°C for 24-48 hours. 
3.3.6 Effects of Nisin and Ferulic Acid on High-Load Listerial Challenge in MLQF.  
Batches of queso fresco were manufactured as described above, but with variation in 
starting inocula and antimicrobial included. Duplicate, independent batches of cheeses were 
prepared with starting inocula of approximately 107 CFU/g L. innocua. Antimicrobials were 
added with the following concentrations: 12.5 µg/g nisin, 2.5 mg/g ferulic acid, or 12.5 µg/g 
nisin combined with 1.0 mg/g  ferulic acid. Cheeses were stored at 4°C and sampled after 0, 1, 3, 
7, 14, 21, and 28 days. 
3.3.7 Effects of Nisin and Ferulic Acid on Low-Load Listerial Challenge in MLQF. 
Batches were manufactured as above, with a lower starting inoculum of L. innocua at 
approximately 103 CFU/g and treated with ferulic acid at concentrations of 2.5 mg/g and 4 mg/g 
with or without 12.5 µg/g nisin. This was then followed up by another two independent batches 
treated with 4.0 mg/g ferulic acid and prepared with an inoculum of approximately 103 CFU/g of 
a L. monocytogenes cocktail. The cocktail was prepared by standardizing the optical density of 
all five L. monocytogenes strains, then combining them in equal proportions by volume and 
serially diluting to the appropriate concentration in sterile water.  
In all batches, ferulic acid was incorporated prior to the centrifugation of the curd, rather 
than directly into the milk, as follows: after inoculation and 15 min incubation to allow Listeria 
to attach to the curd, tubes were centrifuged at 6000 × g for 5 min for incomplete pressing. 
Accessible whey was removed, the antimicrobial treatments were added, and curd was 
centrifuged for another 7 min. The remaining whey was removed and all cheese samples were 
stored at 4ºC for up to 28 days until sampled. 
3.3.8 Compositional Analysis. 
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MLQF samples from three separate manufacturing batches, in addition to a traditional-
scale manufactured batch, were analyzed in triplicate. Dry matter was determined by heating 
samples at 105°C to constant weight (method 926.08; AOAC, 2002). Fat content was determined 
by hydrolysis first with ammonia and then with hydrochloric acid before triple-extraction in a 
Mojonnier-style flask with ethyl ether and ethyl ether/alcohol (method 933.05; AOAC, 2002). 
Total nitrogen was measured via the Dumas combustion method (method 992.15; AOAC, 2002) 
and a protein factor of 6.38 was used to convert total nitrogen to protein (method 2001.14; 
AOAC, 2002). 
3.3.9 Texture Profile Analysis. 
Texture profile analysis (TPA) was carried out in traditional-scale cheeses manufactured 
with the addition of either no antimicrobial or 4.0 mg/g ferulic acid. From each cheese, two 
portions of 20 mm of diameter and 20 mm of height were extracted with a circular mold. Using a 
50 mm cylindrical probe, each sample was compressed twice in a TA-plus texture analyzer with 
NEXYGENPlus 3.0 software (Lloyd Instruments, Hants, UK). A cross-head operating speed of 1 
mm/s, 25% compression, and 0.3 N contact force were selected. Hardness (N), cohesiveness 
(adimensional), springiness (mm), gumminess (N), and chewiness (mJ) were calculated via the 
instrument’s software. For each treatment, TPA was conducted twice on three separate batches 
of cheese. 
3.3.10 Sensory Evaluation. 
Sensory evaluation of the queso fresco samples from the same batch prepared for TPA 
was performed two days after manufacturing. An affective test with untrained panelists (n = 60; 
28 males and 32 females, 18-46 years old) was conducted to evaluate product acceptability of 
queso fresco samples treated with and without 4.0 mg/g ferulic acid. Experimental cheese 
samples were cut into approximately 1.5 cm cubes and allowed to reach room temperature for 30 
min before sensory evaluation. The cheese cubes were identified using randomly generated 3-
digit codes and randomly presented to the untrained panelists. Each panelist was asked to 
evaluate the two cheese samples for appearance, color, aroma, and texture using a 9-point 
hedonic scale of the following values: 1 = dislike extremely, 5 = neither like nor dislike, and 9 = 
like extremely. During sensory evaluation, panelists were asked not to evaluate flavor of the 
samples, because food-grade ferulic acid could not be obtained. 
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3.3.11 Statistical Analysis. 
 Experiments were analyzed as completely randomized designs. Analysis of 
variance was performed using JMP 7.0.1 (SAS Institute Inc., Cary, NC). Cheese composition, 
TPA, and sensory results were evaluated using Student’s t test to determine the statistical 
significance of mean differences between treatments. 
3.4 RESULTS 
3.4.1 Compositional Analysis.  
Production of MLQF is analogous to traditional manufacturing methods in numerous 
ways, primarily the raw ingredients and time-temperature treatments (Fig. 3.1). It varies 
considerably only in scale, with some handling steps necessarily adjusted, including cutting of 
the curd with an inoculating needle instead of a curd knife and centrifugation instead of pressing 
or molding to remove whey. Resulting cheeses closely resemble traditional queso fresco visually, 
but smaller, weighing approximately 0.3 g each. To ensure miniature-scale cheeses were 
compositionally equivalent to traditional queso fresco, cheeses were subjected to analyses to 
determine dry matter, fat, and protein content. The MLQF did not statistically differ from the 
traditional-scale cheese in any of these parameters (Table 3.2). All samples fell within the range 
of compositional values expected for dry matter, fat, and protein, as measured in commercial 
fresh cheeses (Caro et al., 2014). 
3.4.2 Minimum Inhibitory Concentrations. 
The MIC of nisin for L. innocua in BHI was determined to be 12.5 µg/mL. The MIC of 
ferulic acid for L. innocua and each of the L. monocytogenes strains in BHI was determined to be 
2.5 mg/mL. 
3.4.3 Dose-response of Nisin in MLQF. 
To assess the inhibition of Listeria in fresh cheese, nisin was added to a comparable level 
to its MIC in BHI, and a range of greater levels, in the MLQF model. The use of Listeria-
selective agar confirmed that no Listeria were present in the milk or un-inoculated controls and 
allowed for proper enumeration of surviving listerial cells in the presence of non-listerial dairy 
microorganisms. Over 28 days of storage at 4ºC, L. innocua in the untreated control cheeses 
grew nearly 2 log CFU/g (Fig. 3.2). Treatment with nisin reduced survival of L. innocua during 
the first week in a dose-dependent fashion. The cheeses treated with 12.5 µg/g and 25 µg/g nisin 
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reduced L. innocua levels by approximately 1 log CFU/g, while 100 µg/g to 400 µg/g nisin 
reduced levels by approximately 2 log CFU/g. The cheeses treated with 200 µg/g and 400 µg/g 
remained low through the first week of storage, while the other treated cheeses had recovered up 
to 1 log CFU/g. By the end of the 28-day storage, all treated cheeses had recovered to levels 
comparable to the control. 
3.4.4. Effects of Nisin and Ferulic Acid on High-Load Listerial Challenge in MLQF. 
The MIC of ferulic acid for the listerial strains tested in BHI was used on a cheese-weight 
basis for inclusion in MLQF. Figure 3.3 shows the antimicrobial effect against L. innocua of 
nisin, ferulic acid, and their combination when added to MLQF. Over 28 days of storage at 4°C, 
the L. innocua present in untreated control cheeses grew approximately 1.5 log CFU/g. ferulic 
acid showed an inhibitory effect preventing L. innocua from growing more than approximately 
one quarter log CFU/g over the 28 day storage. Nisin demonstrated approximately one half log 
CFU/g reduction over the first 3 days, but regrowth occurred shortly thereafter and the load of L. 
innocua remained similar to that of the control at the end of 28-day storage. The combination of 
nisin and ferulic acid showed the greatest initial reduction, approaching a 1 log CFU/g decrease 
after 7 days of storage, but regrowth also occurred and by the end of storage the levels of L. 
innocua had risen just above that of the cheeses with ferulic acid alone. 
3.4.5 Effects of Nisin and Ferulic Acid on Low-Load Listerial Challenge in MLQF. 
In the next set of cheeses, featuring a lower starting inoculum, nisin alone provided minor 
inhibition of L. innocua growth only in the first week and grew from approximately 3 log CFU/g 
to over 8 log CFU/g, much like the untreated control. Both additions of nisin in combination with 
ferulic acid showed reductions of almost 1 log CFU/g of L. innocua after only 1 day of storage, 
but after 3 days the levels of L. innocua were similar to those treated with ferulic acid alone (Fig. 
3.4). However, after 28-day storage, cheeses treated with 2.5 mg/g or 4.0 mg/g ferulic acid 
remained approximately 2.5 log CFU/g and 3.5 log CFU/g lower than the control, respectively. 
After establishing and validating model parameters with L. innocua, as a surrogate 
organism for extra safety during initial antimicrobial testing, we then confirmed the observed 
antimicrobial activity of ferulic acid against L. monocytogenes. Follow-up with a cocktail of 
different L. monocytogenes strains in the fresh cheese model (Fig. 3.5) showed a slower growth-
rate in the control cheese and a greater level of inhibition by treatment with 4.0 mg/g ferulic acid; 
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less than one half-log CFU/g growth occurred in the presence of ferulic acid after 21 days, 
remaining 3 log CFU/g lower than the untreated control.  
3.4.6 Texture Profile Analysis. 
Texture profile analysis (TPA) of traditional-scale queso fresco was performed to assess 
the impact of treating cheeses with 4.0 mg/g ferulic acid on the structural quality of cheese 
samples. Relative to the control, springiness and chewiness were significantly lower in cheese 
treated with ferulic acid (Table 3.3). However, no differences in cohesiveness, gumminess, or 
hardness were observed; each cheese demonstrated the characteristically crumbly texture of 
queso fresco. 
3.4.7 Sensory Evaluation. 
Ferulic acid is not currently an approved food additive in its purified form, so food-grade 
ferulic acid was unavailable to allow for consumers to assess the flavor of treated cheeses. No 
significant differences in consumer acceptability of appearance, color, aroma, or texture were 
observed between the control and samples of queso fresco treated with ferulic acid (Table 3.4).  
3.5 DISCUSSION 
Our miniaturized queso fresco model generates cheeses from batches of milk that can be 
scaled to suit any experimental replication. This is accommodated by incorporating antimicrobial 
treatments and rennet prior to distribution into microcentrifuge tubes for incubation. The 
production process for each cheese is carried out entirely in a single vessel, including 
centrifugation of the curd to replace conventional cheese pressing methods that are less feasible 
at the miniature scale. Similar small-scale production has previously been shown to have little 
impact on the quality and microstructure of cheese relative to pilot- and commercial-scale 
manufacturing (Bachmann et al., 2009). We have demonstrated that our MLQF model is 
compositionally analogous to traditionally produced fresh cheese, with equivalent fat, protein, 
and moisture content.  
Nisin has been used as a preservative in the food industry for decades. A broad-spectrum 
bacteriocin produced by Lactococcus lactis, nisin inhibits many Gram-positive organisms 
including the food-borne pathogen Listeria monocytogenes (Gálvez et al., 2007). This has made 
nisin particularly useful for inhibiting growth of L. monocytogenes, among others, in processed 
foods ranging from cheeses to sausages and smoked meats. We found that the MIC of nisin for 
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L. innocua ATCC 33090 in laboratory media is comparable to that of numerous L. 
monocytogenes strains (Davies and Adams, 1994; Techathuvanan et al., 2014), consistent with 
its common use as a model organism for investigating antilisterials. However, elaboration of 
antimicrobial activity in laboratory media may not always be an appropriate indicator of activity 
when incorporated into a food matrix. For example, the activity of nisin has been shown to be 
affected by milk-fat composition of dairy (Jung et al., 1992), possibly due to adsorption to 
protein or fat globules or heterogeneous distribution of the compound and bacteria. Nutrient 
composition may also result in significant discrepancies between antimicrobial activity observed 
in lab media and in cheese (Collins et al., 2011). Additionally, antilisterial activity of nisin has 
been shown to be more effective at low pH compared to neutral or alkaline conditions 
(Benkerroum and Sandine, 1988; Davies et al., 1997). Therefore, nisin may exhibit reduced 
activity in near-neutral pH fresh cheeses. As such, we wished to compare the inhibitory activity 
of nisin in laboratory media to incorporation within a queso fresco matrix. 
We observed a dose-dependent inhibition of L. innocua in queso fresco (Fig. 3.2) at 
levels of nisin comparable to the concentrations tested in BHI, relative to the volumes of milk 
used and final yield of the cheeses. Above 100 µg/g there appeared to be diminishing returns. 
Even at a treatment of 400 µg/g, which exceeds the US regulatory limit of 250 ppm (U.S. Food 
and Drug Administration, 1988), inhibition of L. innocua did not exceed 2 log CFU/g under the 
tested conditions. Outgrowth of surviving organisms resulted in no treatments displaying 
considerable inhibition relative to the control after three weeks of storage. Nisin has been known 
to alter the cell membrane lipid composition of listerial populations, decreasing membrane 
fluidity and preventing further pore-formation, thereby limiting further activity by bacteriocins 
(Ming and Daeschel, 1995; Mazzotta and Montville, 1997). However, regrowth may not have 
been due to the emergence of resistant L. innocua strains, because several isolates of L. innocua 
that were recovered after 28 days in MLQF demonstrated identical MIC as the starting inocula 
(data not shown). Nisin may simply not be stable enough in fresh cheese, particularly due to its 
near-neutral pH, to remain active for extended periods or its activity may be inherently limited 
by the cheese matrix. While nisin was somewhat effective at preventing the growth of Listeria, 
queso fresco would likely benefit from additional hurdles to promote further inhibition and avoid 
the potential development of resistance to nisin. 
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Ferulic acid is a phenolic phytochemical that has been shown to exert antilisterial 
preservation in some food matrices (Takahashi et al., 2013). Ferulic acid is abundant in cell walls 
of cereals like wheat, corn, and rice, making it relatively accessible antimicrobial additive for the 
food industry (Ou and Kwok, 2004). Phenolic acids, such as ferulic acid, generally inhibit 
bacterial growth by increasing the permeability of cell membranes, often driving leakage of 
cytoplasmic components (Campos et al., 2009; Borges et al., 2013). Furthermore, Takahashi et 
al. (2015) demonstrated that L. monocytogenes is less likely to develop resistance to the effects 
of ferulic acid than to nisin. Ferulic acid thereby seemed an appropriate adjunct to pair with nisin 
in a combined antilisterial approach for queso fresco. 
Initial tests began with a high level of listerial contamination to determine the maximum 
antimicrobial efficacy of the treatments against a bacterial load far greater than that likely 
encountered during cheese production. Nisin and ferulic acid, in combination, initially resulted in 
greater reduction in the survival of L. innocua than either alone. However, the inhibition 
observed in cheeses treated with 2.5 mg/g ferulic acid led to lower listerial load than the 
combination treatment after 28 days of storage (Fig. 3.3), while nisin-treated cheeses recovered 
to levels similar to the control. The lower dose of ferulic acid used in combination with nisin 
could account for the lesser inhibitory effect, which called for testing additional concentrations 
of ferulic acid, alone and in combination with nisin. 
We tested these at lower starting inocula to reflect contamination levels more likely to be 
encountered during industrial cheese production, based on what has been measured in 
contaminated retail products (Beckers et al., 1987; Pini and Gilbert, 1988), and better assess the 
inhibitory effects of ferulic acid on cell growth. Interestingly, the combinations of nisin and 
ferulic acid were no more effective than ferulic acid alone after the first three days of storage 
(Fig. 3.4). Nisin alone demonstrated minimal inhibition of listerial growth under these 
conditions. Similarly, ferulic acid was less inhibitory than in the previous trial, though it 
remained significantly more inhibitory than nisin. Perhaps reduced bacterial saturation provided 
improved conditions for L. innocua to resist injury by these compounds, either due to the 
antimicrobial doses chosen or differing effects on membrane permeability given the conditions 
of the cheese matrix. Regardless, the inhibition by ferulic acid alone suggests that its 
combination with nisin demonstrated additive inhibition that could warrant future investigation 
into combinations with other antimicrobials. 
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Due to its promising inhibitory activity, we then confirmed that ferulic acid is inhibitory 
toward a cocktail of L. monocytogenes strains (Fig. 3.5). We worked primarily with L. innocua 
for safety and expediency during development of the cheese model, but L. innocua is not always 
considered an appropriate surrogate for L. monocytogenes without critical evaluation of their 
behaviors, particularly when exposed to complex environments and stressors (Milillo et al., 
2012). L. innocua demonstrated a similar, but higher growth rate and tolerance to ferulic acid 
relative to the L. monocytogenes cocktail, which confirms that L. innocua is an appropriate 
surrogate for screening ferulic acid against L. monocytogenes in fresh cheese. To our knowledge, 
this also constitutes the first comparison between the growth of L. innocua and L. monocytogenes 
under antimicrobial stress within a cheese matrix. Following our challenge studies, we explored 
the feasibility of such ferulic acid supplementation as a preventative measure in commercial 
queso fresco with preliminary assessments of its impact on acceptability. 
Plant extracts and essential oils have been known to negatively impact sensory attributes 
of some cheeses (Tornambé et al., 2008). We tested the inhibitory activity of a pure form of 
ferulic acid to minimize the potential of affecting the flavor of the cheeses. Ferulic acid is 
approved as a food additive for its antioxidant properties in Japan, but in most countries only 
holds regulatory approval in the form of natural extracts and essences (Ou and Kwok, 2004). We 
could therefore not assess the impact of ferulic acid on cheese flavor, but proceeded with various 
texture and sensory characterizations. We tested the inclusion of the highest concentration of 
ferulic acid as constructed in the laboratory to maximize the likelihood of noticeably altering the 
product. Consumers demonstrated no difference in preference between the cheeses with regards 
to appearance, color, or aroma. These results are encouraging for the future use of ferulic acid as 
a commercial preservative and suggest that more rigorous sensory analysis may be appropriate 
once food-grade ferulic acid is available. 
In summary, we have demonstrated a facsimile of traditional queso fresco at such a scale 
that it can be manufactured in complete biocontainment, uses minimal amounts of antimicrobial, 
and allows for artificial contamination or treatment of the production process at any stage. Such 
flexibility warrants further exploration of what production factors may impact antimicrobial 
efficacy. Future work could focus on further varying microbial contamination and antimicrobial 
treatment levels, as well as the timing of their introduction. Similarly, processing variables such 
as the duration and temperature of each step could be adjusted to assess their roles in the 
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proliferation of spoilage organisms and pathogens. Once food-grade ferulic acid is available, the 
MLQF model may prove useful for identifying synergistic combinations with other common or 
novel antimicrobials. 
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3.8 TABLES AND FIGURES 
Table 3.1. Strains of Listeria  
Listeria strain 
Listeria innocua ATCC 33090 
Listeria monocytogenes ATCC 19112 
Listeria monocytogenes ATCC 7644 
Listeria monocytogenes 10403S 
Listeria monocytogenes SLCC-5764 
Listeria monocytogenes ATCC 13932 
 
Table 3.2. Dry matter, protein content, and fat content of miniaturized laboratory queso fresco 
(MLQF) and a traditional-scale queso fresco 
Cheese batch MLQF  Traditional scale 
Dry matter (%) 44.43 ± 1.16a 46.14 ± 0.56a 
Protein (%) 18.25 ± 0.31a 18.34 ± 0.23a 
Fat (%) 22.35 ± 1.14a 23.54 ± 0.17a 
a Means with dissimilar letters within each row are significantly different (p < 0.05) 
1 Values are means ± SEM 
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Table 3.3. Texture profile analysis properties of queso fresco treated with ferulic acid1 
 Control Ferulic acid 
Hardness (N) 4.19 ± 0.16a 4.62 ± 0.12a 
Cohesiveness 0.77 ± 0.02ª 0.84 ± 0.02ª 
Springiness (mm) 3.36 ± 0.24a 2.15 ± 0.32b 
Gumminess (N) 8.67 ± 0.35a 8.78 ± 0.24a 
Chewiness (mJ) 11.75 ± 0.89a 7.71 ± 1.19 b 
a,b Means with dissimilar letters within each row are significantly different (p < 0.05) 
1 Values are means ± SEM 
 
 
Table 3.4. Consumer acceptability of queso fresco with added ferulic acid 
 Acceptability1 
Antimicrobial Appearance Color Aroma Texture 
None 7.08 ± 0.17a 7.32 ± 0.13a 6.40 ± 0.20a 6.62 ± 0.21a 
Ferulic acid 7.17 ± 0.16a 7.13 ± 0.14a 6.13 ± 0.21a 6.75 ± 0.19a 
aMeans with dissimilar letters within each column are significantly different (p < 0.05) 
1Consumer acceptability was based on a 9-point scale (1 = dislike extremely, 5 = neither like nor dislike, and 9 = 
like extremely). Values are means ± SEM 
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Figure 3.1. Flow diagram of miniaturized laboratory queso fresco (MLQF) production. Asterisks 
indicate potential points of microbial contamination or antimicrobial treatment: in the milk 
before or during renneting (A), during the curd cutting (B), during salting, during holding of the 
curd (C), during “pressing” via centrifugation (D), or on the cheese surface during storage (E).  
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Figure 3.2. Effect of nisin on the survival of L. innocua in a fresh cheese model stored at 4°C. 
Nisin was added to cheeses by weight, with final concentrations of 0 µg/g (○), 12.5 µg/g (●), 25 
µg/g (□), 100 µg/g (■), 125 µg/g (△), 200 µg/g (▲), and 400 µg/g (◊). Values are means ± SEM. 
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Figure 3.3. Effect of nisin and ferulic acid on survival of L. innocua in fresh cheese after storage 
at 4°C. Nisin and ferulic acid were added to cheeses by weight, with final concentrations of 0 
µg/g (○), 12.5 µg/g nisin (●), 2.5 mg/g ferulic acid (□), and 12.5 µg/g nisin + 1 mg/g ferulic 
acid (■).Values are means ± SEM. 
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Figure 3.4. Effect of nisin and different concentrations of ferulic acid on survival of L. innocua 
in fresh cheese after storage at 4°C. Nisin and ferulic acid were added to cheeses by weight with 
final concentrations of 0 µg/g (○), 12.5 µg/g nisin (●), 2.5 mg/g ferulic acid (□), 4.0 mg/g 
ferulic acid (■), 12.5 µg/g nisin + 2.5 mg/g ferulic acid (△), and 12.5 µg/g nisin + 4.0 mg/g 
ferulic acid (▲).Values are means ± SEM. 
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Figure 3.5. Effect of ferulic acid on survival of a L. monocytogenes cocktail in a fresh cheese 
after storage at 4°C. Ferulic acid was added to cheeses by weight, with final concentrations of 0 
mg/g (○), 4.0 mg/g ferulic acid (●). Values are means ± SEM.  
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CHAPTER 4: LISTERIA AND THE ENGINEERING OF ANTIMICROBIAL ENZYMES4 
4.1 ABSTRACT 
Cell wall lytic enzymes have been of increasing interest as antimicrobials for targeting 
Gram-positive spoilage and pathogenic bacteria, largely due to the development of strains 
resistant to antibiotics and bacteriophage therapy. Such lysins show considerable promise 
against Listeria monocytogenes, a primary concern in food-processing environments, but there is 
room for improvement via protein engineering. Advances in antilisterial applications could 
benefit from recent developments in lysin biotechnology that have largely targeted other 
organisms. Herein we present various considerations for the future development of lysins, 
including environmental factors, cell physiology concerns, and dynamics of protein architecture. 
Our goal is to review key developments in lysin biotechnology to provide a contextual 
framework for the current models of lysin-cell interactions and highlight key considerations for 
the characterization and design of novel lytic enzymes. 
4.1.1 Highlights. 
 Recombinant lytic enzymes have several advantages over bacteriophage treatments. 
 Types and sources of binding and catalytic domains greatly impact lysin efficacy. 
 Viral enzymes and bacterial autolysins offer diverse reservoirs for recombination. 
 Lysins hold promise for being tailored to specific applications with careful design. 
 Enzyme architecture, cell physiology, and environment are key design considerations. 
4.2 REVIEW 
4.2.1 Introduction. 
Listeria monocytogenes is a Gram-positive foodborne pathogen that can cause a severe 
illness, listeriosis, especially in young, elderly, pregnant and immunocompromised individuals. 
While the incidence of listeriosis is rare, the high fatality rate has resulted in the US declaring L. 
monocytogenes as one of three zero tolerance microorganisms in ready-to-eat (RTE) foods. L. 
monocytogenes is adept at forming biofilms within food processing facilities wherein they can 
persist for years despite frequent sanitation [1]. Once L. monocytogenes gets into a RTE food, 
                                                 
4 This chapter appeared in its entirety in the journal Current Opinion in Biotechnology: Van Tassell M.L., Daum 
M.A., Kim J.S., Miller M.J., 2016. Creative Lysins: Listeria and the Engineering of Antimicrobial Enzymes. Curr. 
Opin. Biotech. 37:88-96. This article is reprinted with the permission of the publisher and is available online at 
http://www.sciencedirect.com and using DOI: 10.1016/j.copbio.2015.10.006. 
70 
 
there is the potential for this organism to grow during refrigerated storage. This is especially 
important for foods where current antilisterials are not effective, such as Hispanic-style fresh 
cheeses. With the rise of microbial antibiotic resistance and regulations limiting the use of 
antibiotics in the food chain, alternative antimicrobial methods are of growing interest. In this 
review, we discuss the potential for using and improving bacteriophage endolysins to combat L. 
monocytogenes in the food environment. 
4.2.2 Phage Against the Machine: Bacteriophage Applications in the Food Industry. 
Bacteriophages (phages) are viruses that infect and kill bacteria. The application of lytic 
phages is a promising approach to managing L. monocytogenes in foods and their manufacturing 
environments. In fact, there are several examples in the literature where listerial phages have 
been successful at reducing L. monocytogenes populations on food processing equipment and 
directly in foods [2]. There are currently two commercial listerial phage products that are 
available and approved for use in the US: Listex P100 and ListShield. 
Despite their successful application, phages have significant limitations. First, their 
limited host range typically requires the use of a combination of phages with overlapping host 
ranges. Alternatively, a broad host range phage could be used if identified, but it is unlikely that 
the host range for any single phage could encompass every strain within a given species. Second, 
the rate for bacteria to become phage resistant is a significant concern. For both reasons, active 
surveillance of the target population would be necessary to quickly determine when new strains 
arise that are either insensitive or resistant to phage applications [3]. Unfortunately, application 
specific factors can greatly affect the rate of phage resistance and thus require experimental 
assessment for each situation [4]. 
The process of identifying which phages are the best for a particular application is critical 
for the successful application of phages by the food industry. Examination of phage-bacterial 
population dynamics in the appropriate environment has the potential to inform which phages 
should be used for a desired application [4]. For example, modeling may inform which 
adsorption rate, burst size and lytic time is best for a particular application. Identification of host 
receptors for various phages can enable the application of phage cocktails that target different 
receptors which decreases the rate of phage resistance [5]. Clearly, isolating host phages from the 
environment is only the first step in successful application of phages by the food industry. 
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Attempts to improve phages by various biotechnological approaches show some promise 
for improved functionality [6], such as adding genes that encode for proteins that disrupt 
biofilms [7 and 8]. Despite biotechnological innovations, fundamental limitations of the bacteria-
phage relationship remain [9], resulting in a trade-off between phage replication, stability, and 
host range. In particular, evolutionarily successful phages must balance virulence against the 
preservation of host populations for continued exploitation [10]. The properties that make a 
phage successful in one environment are not necessarily those that are optimal for food industry 
applications, where the elimination of host populations is the primary goal. 
4.2.3 In Lysis We Trust: Endolysins as Antilisterials. 
Bacteriophage endolysins are peptidoglycan-degrading enzymes necessary for 
completion of the phage lytic cycle (Figure 4.1A). Responsible for ‘lysis-from-within’ (Figure 
4.1B), endolysins typically bypass the cell membrane via viral holin proteins and degrade the cell 
wall so that the host cells lyse from osmotic pressure and release progeny phage virions. 
However, the exogenous application of endolysins as antimicrobial treatments has received much 
interest in light of antibiotic resistance concerns and the limitations of phage therapies and other 
antimicrobials. Endolysins can independently degrade the cell walls of Gram-positive organisms, 
in what is often referred to as ‘lysis-from-without’ (Figure 4.1C). Such an approach features 
much of the specificity of phage application, and the benefits therein, but avoids concerns of 
evolving resistant organisms. No bacteria have been shown to develop resistance to endolysins, 
likely due to the targeted destruction of relatively conserved cell wall structures [11]. 
In general, endolysins from Gram-positive phages are primarily modular in structure with 
one or two N-terminal enzymatically active domains (EADs) and one or more C-terminal cell-
wall binding domains (CBDs). These lytic enzymes are also characterized by the nature of their 
target substrate (Figure 4.1D), which is dictated by the catalytic function of the EAD. CBDs bind 
to various cell wall constituents to promote the localization of the EAD with its substrate, 
enhancing catalytic efficiency and conferring some additional target specificity (see [12•] for 
further discussion). 
In contrast, endolysins of bacteriophages from Gram-negative organisms are typically 
globular proteins, though some have modular structure with an inverse architecture relative to 
Gram-positive lysins. Progress is now being made with Gram-negative endolysins in 
antimicrobial applications despite challenges their outer membranes present [13], but here we 
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focus on discussion of endolysins affecting Gram-positive organisms relevant to the food 
industry such as Listeria monocytogenes, Staphylococcus aureus, Clostridium 
perfringens, Bacillus cereus, and lactic acid bacteria. Similar types of other peptidoglycan lytic 
enzymes exist, as discussed briefly in Box 1, and collectively we will refer to all of these 
functionally related enzymes as ‘lysins’. 
4.2.4 Box 1: Novel Sources of Cell-Wall Hydrolases. 
Bacteriophage endolysins have been some of the most intensely investigated bacterial 
cell wall hydrolases, perhaps due in part to the expediency of their identification. If an organism 
can be infected by a lytic bacteriophage, then the phage necessarily carries the gene for an 
endolysin that can produce lysis. Many bacteriophages also feature virion-associated 
peptidoglycan hydrolases, primarily on the phage baseplates or tail-fibers, which degrade the cell 
wall exterior to an extent that facilitates infection [21]. These enzymes have been implicated in 
the lysis-from-without observed with particularly high phage multiplicities-of-infection [22] and 
constitute a relatively under-explored class of potential antimicrobials. 
The array of known phages serves as a vast reservoir of genetic diversity from which 
scientists can draw to engineer new lytic enzymes. However, the genomes of target organisms 
are also rife with similar hydrolases dubbed ‘autolysins’, which facilitate cell wall repair, 
maintenance, and programmed cell death. Perhaps evolutionarily related to viral endolysins [23], 
bacterial autolysins have also been shown to effectively inhibit microbial growth via exogenous 
application, including that of L. monocytogenes [20]. More in-depth exploration of autolysins has 
been performed in S. aureus [24], further establishing autolysins as a reservoir for novel 
antimicrobials. Furthermore, genes for hydrolytic enzymes present in prophages may serve as 
additional sources of novel genetic diversity [25]. These can be identified within target genomes 
with prophage search tools such as PHAST [26]. Along with autolysins, these genes may be 
particularly useful should known phage isolates not be available, such as when seeking 
antimicrobials for emerging pathogens or other understudied organisms. 
4.2.5 If You’ll Pardon the Expression: Applications of Recombinant Lysins. 
Recombinant expression of phage lysins has become a powerful tool to investigate their 
function and potential uses. Just as application of listerial phages has expanded for biocontrol in 
the food industry, so too has exploration of listerial phage endolysins. Early work has included 
the proof-of-concept expression of listerial endolysins in lactic acid bacteria as biopreservatives 
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for dairy applications [14 and 15]. The amidase LysZ5, purified from recombinant expression 
in Escherichia coli, was more recently shown to effectively inhibit listerial growth in refrigerated 
soya milk [16]. Listerial endolysins have also been successfully immobilized in food-grade 
nanoparticles and polymer films, demonstrating both cell lysis in vitro and inhibition of listerial 
growth on lettuce [17••]. These types of immobilization technologies could potentially lead to 
treatments of equipment surfaces in food processing facilities, for example, to limit cross-
contamination and address listerial persistence issues. Likewise, work with lysins as biofilm 
control agents, while having largely focused on clinical pathogens thus far [18 and 19], could 
also greatly benefit food processing environments. A listerial amidase has already been 
demonstrated to effectively disrupt listerial biofilms [20], but only when combined with another 
protease. 
Lysins specific for a wide variety of organisms have been isolated, including many of 
clinical and industrial relevance such as S. aureus and L. monocytogenes. Now the manipulation 
of lysin genes, to add, subtract, and rearrange domains of their modular architecture, is of 
considerable interest to improve enzymatic functionality. These protein engineering approaches 
seek to produce designer chimeric enzymes of greater antimicrobial effect than wild-type 
enzymes, but have thus far generally required trial-and-error to determine the most appropriate 
ways for shuffling functional domains within lysins. Here we present a number of considerations 
for the recombination of lysins that have become evident from recent works in the field, as well 
as opportunities for further exploration. 
4.2.6 Eminent Domains: Cell-Binding Modules of Lysins. 
Designing effective recombinant lysins for a given application often appears to depend on 
carefully weighing the impacts on antimicrobial activity and lytic spectrum. Since the 
recombination of lysin domains helped to establish the nature of their modular architecture [27], 
CBDs have been mixed-and-matched or even removed from parental genes to modulate 
enzymatic activity (see [28] for in-depth discussion). CBDs can focus enzymatic activity of 
endolysins on the target organism and enable efficient catalysis on the cell wall surface (Figure 
4.2A), so removal of CBDs via truncation can result in the loss of antimicrobial capacity from 
diminished binding affinity ( Figure 4.2B) [ 29, 30 and 31]. 
However, the removal of CBDs from some endolysins has been demonstrated to actually 
increase lytic activity relative to the parental enzymes [14, 32, 33, 34, 35 and 36]. This appears in 
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some situations to be due to truncation resulting in a smaller enzyme that may reach its substrate 
more readily, bypassing obstructions to the cell wall and accessing specific target linkages within 
the peptidoglycan matrix [35]. Furthermore, some lysins may feature a CBD that contributes a 
degree of autoinhibition, allowing the EAD to function only when bound to specific well wall 
structures [37]. CBD removal in these instances alleviates allosteric constraints, resulting in 
constitutively active EADs. This may also result in removing limitations of specificity 
contributed by the CBD (Figure 4.2C). 
4.2.7 Home on the Range: Lytic Spectra of Lysins. 
The recombination of CBDs within a lysin will impact its lytic spectrum, or the diversity 
of organisms the enzyme can lyse. As seen with listerial CBD fusions, combining CBDs from 
endolysins with different lytic spectra can create a chimeric enzyme with an additive spectrum 
[40]. In some instances, the lytic spectrum appears to be retained when the CBD is truncated 
from the lysin [43]. However, numerous lysins have also been found to broaden lytic spectra 
against non-host organisms, such as related species or serovars, upon CBD removal 
[35, 36 and 37]. It appears that this may be reliant upon the net charge of the EAD. EADs may 
require a positive net charge for independent function apart from a CBD that could otherwise 
help overcome electrostatic repulsion from the predominantly negatively charged cell surface 
[35] (Figure 4.2D). While chimeric enzymes with synergistic CBDs may improve lytic spectra of 
lysins with EADs that are dependent upon CBDs, it also appears feasible to manipulate their 
charge to remove the necessity of CBDs in some situations [35 and 44]. Whether these truncated 
EADs remain as functional when applied in complex food environments remains to be seen, 
however (see Box 2 for further discussion). 
Furthermore, the charge of interdomain linker regions, and their impact on lysin 
conformation, may play a critical role in lytic activity and spectrum [19 and 45]. Some 
endolysins even demonstrate autoproteolytic cleavage of linker regions [46••] or alternative 
translation patterns [47], which may have implications regarding the prevalence and 
manipulation of lysin oligomerization. The sequence-specificity of such mechanisms also 
suggests further nuance to the compatibility of modular domains in some lysins. 
4.2.8 Box 2: Environmental Impacts on Hydrolytic Activity. 
As with all enzymes, the activity of endolysins is impacted by the environment in which 
they function. Environmental pH, temperature, and ionic strength can all affect intramolecular 
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interactions, impacting enzymatic stability and activity rate [38]. Lysins may also not be 
compatible with other chemical compounds, for example components of a complex food matrix. 
The presence of chelators like EDTA or citrate can sequester ions essential for the function of 
some lysins, such as zinc or manganese, abolishing lytic activity. 
Recently a chimeric lysin has been developed through combination of a pathogen-
specific CBD with an EAD from a thermophilic phage lysin to increase stability at elevated 
temperatures [39•]. This approach to protein engineering highlights the potential for tailoring 
enzymatic design to specific applications. For activity during food processing and storage, 
stability under specific environmental conditions such as exposure to detergents or low 
temperatures should be considered. CBD duplication in a listerial lysin has been shown to 
promote lytic activity in the presence of high salt concentrations [40], which may be useful for 
biocontrol in cured meats or cheeses. Similarly, dimerization of lysins has demonstrated both 
improved activity and stability in vivo [41]. Though difficult to predict, such approaches to 
protein engineering may facilitate further improvement to the application of endolysins in new 
areas. Alternatively, methods of directed evolution show considerable promise for improving 
parameters such as lysin thermostability [42] and warrant further exploration to screen for other 
novel modifications of increased functionality. 
4.2.9 Tag, You’re It! Affinity Tags on Lysins. 
The presence and location of a protein tag, such as poly(His), for the affinity purification 
of a recombinant lysin could also be a significant consideration. Whether on the N-terminus or 
C-terminus of the protein, there is potential to alter conformation of the enzyme and negatively 
impact lytic activity. Some lysins necessitate C-terminal tagging [25 and 48], but others may 
require, or at least allow, N-terminal tags [49]. Unfortunately, optimal configuration must be 
determined empirically for a given lysin. 
4.2.10 Up against the Wall: Interactions of Lysins with Cell Surfaces. 
Not only does the domain architecture of a lysin impact its antimicrobial activity, but the 
enzyme class, growth phase and cell structure of the target organism are of considerable 
importance. Muramidases and glucosaminidases cut highly conserved linkages present on all 
Gram-positive bacteria. However, different bacterial strains have evolved mechanisms to protect 
those linkages [50 and 51]. N-deacetylation or O-acetylation of the cell wall glycans can inhibit 
enzymatic binding and catalysis. Amidation of the crosslinking peptide bridge can interfere with, 
76 
 
or assist, endopeptidase action [52 and 53]. Each of these structural modifications can also 
influence the local charge of the cell wall and thereby the electrostatic compatibility with 
enzymatic domains as discussed above. 
Similarly, the presence of wall teichoic acids (WTAs) should also be taken into 
consideration, particularly in L. monocytogenes, wherein it comprises up to 70% of the cell wall 
by weight and varies compositionally across serovars [ 54• and 55]. WTAs can restrict access of 
some endolysins to the cell surface, limiting activity to the poles and cell septa. In contrast, WTA 
may actually facilitate the binding of some lysins [56], depending on its composition, so 
compatibility of a lysin with the ligands of both its EAD and CBD should be established to 
optimize lytic activity. 
4.2.11 Mid-Life Lysis: Enzymatic Activity and Cell Physiology. 
Alteration of WTA composition and the degree of peptidoglycan cross-linking in cell 
walls differs in response to the environment and the stage of the bacterial life cycle [57], each of 
which dramatically influences susceptibility to lysis-from-without. Often, stationary-phase cells 
appear more resistant to lytic activity of endolysins than exponential-phase cells [25 and 58]. 
Ironically however, these observations are generally not derived from the assessment of lytic 
activity under conditions of active cell growth. Commonly in turbidity reduction assays used to 
assess lytic activity, cells are harvested at a certain stage of growth and resuspended into a non-
nutritive buffer wherein they are challenged with endolysin while held statically at a particular 
physiological state. Assays using intact, but metabolically inert cells, or even purified or crude 
peptidoglycan extracts, may provide a good indication of whether a target organism may be 
susceptible to enzymatic action, but may not translate to lysis of growing cells [59 and 60]. 
Turbidity reduction, spot-on-lawn, zymogram, and minimum-inhibitory-concentration assays, as 
well as differences in the preparation of cells for their use, all reflect subtly different 
characterizations of lysin-target interactions [60] and do not necessarily reflect antimicrobial 
activity in the context of its desired therapeutic or preventative use, such as in a food matrix. 
While there is precedent for the successful use of lysins in food products [16 and 17••] that 
confirm functionality of lysins against growing cells, in vitro results may not always extrapolate. 
When interpreting the literature surrounding lysin characterization, care should be taken to 
consider these discrepancies, particularly when making comparisons between studies using 
different methodologies and cell preparations. 
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4.2.12 Death by a Thousand Cuts: Lysis-from-Without. 
Despite how they are often visualized, bacteria are not simply dissolved by the 
degradative action of hydrolytic enzymes. A hole must form in the peptidoglycan past a critical 
size threshold, which is estimated to be 15–24 nm in Gram-positive cells [61•]. As a sufficiently 
large pore is established, the cell membrane prolapses and eventually ruptures from the 
uncontrolled release of internal turgor pressure. The number of peptidoglycan linkages necessary 
to be hydrolyzed for such a rupture is unclear. Perhaps as few as 5% of cell wall linkages must 
be cleaved to effect lysis for the majority of cells [62], but their localization on the cell surface 
and environmental factors that impact turgidity and cell membrane permeability also likely affect 
susceptibility [63]. The number of linkages cleaved by each lysin and the dose necessary to 
effect lysis likely varies with each of the aforementioned environmental, lysin configuration, and 
cell physiology considerations. 
4.2.13 Fatal Attraction: a Disadvantage to High-Affinity Binding. 
Another opportunity for further exploration involves the hypothesis that phages may have 
evolved endolysins with high binding affinities for specific host targets to minimize the release 
of free enzymes post-lysis [29]. Otherwise, the free lysin may prematurely kill neighboring cells 
and disrupt viral spread. A listerial lysin with cell binding affinity enhanced via CBD duplication 
demonstrated limited lytic activity [40], highlighting a trade-off between binding affinity and 
potential surface mobility that has otherwise been poorly characterized. While evolution may 
have facilitated heightened affinity to limit unnecessary cell death, perhaps some adaptation may 
be accomplished via recombination to maximize the spread of endolysins and their 
indiscriminate destruction of target organisms, avoiding sequestration by the debris of long-
fallen cells. This approach, and whether it would best be suited to the absence or careful design 
of CBDs within a lysin, has not been addressed to our knowledge. 
4.3 CONCLUSIONS 
Lysins demonstrate considerable potential as antimicrobial treatments, including as 
environmental disinfectants (Hoope et al., 2009), against several clinically relevant organisms. 
However, there is room for further exploration and optimization against numerous pathogens of 
concern. Endolysins may be particularly suited to addressing concerns with Listeria, which poses 
a persistent hazard that has been resilient to various means of disinfection in the food industry 
[1]. Current approaches to lysin discovery and engineering largely depend on the empirical 
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assessment of lytic activity and specificity, as there is no way to reliably predict the lytic 
spectrum and specific activity of a lysin beyond some comparisons of homology to those of 
known structure or function. Comprehensive knowledge of the parameters that impact lysis in a 
given application is advantageous towards integrating such factors in a holistic approach to lysin 
design. In particular, cell physiology and environmental factors should be taken into account to 
avoid the risks of making inappropriate assumptions regarding lysin suitability in a given 
situation. This may be especially relevant in complex, dynamic environments such as those 
encountered by organisms throughout the food supply. Lysin-target compatibility must be 
adapted to account for these factors in desired applications. At the very least, these constitute 
elements of concern during design and trouble-shooting for those assessing novel lysins as 
antimicrobials. 
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Figure 4.0. Graphical Abstract 
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Figure 4.1. Lysis by phage endolysins. Lysis by phage endolysins. Bacteriophages infect target 
cells in order to replicate (a), but release of progeny phages requires lysis-from-within (b) that 
results from endolysins penetrating the cell membrane with the assistance of phage holin proteins 
and hydrolyzing the cell wall. Gram-positive organisms are also susceptible to cell wall 
degradation by endolysins applied exogenously, in what is referred to as lysis-from-without (c). 
Cell wall peptidoglycan can be hydrolyzed by different classifications of enzymes depending on 
the specific linkages that are targeted (d); N-acetyl-β-d-muramidases — also called lysozymes —
 andN-acetyl-β-d-glucosaminidases hydrolyze the glycosidic linkages of the peptidoglycan 
backbone, N-acetylmuramoyl-l-alanine amidases cleave the initial alanine residue of the stem 
peptides from muramic acid, and endopeptidases cleave specific linkages within the peptide 
stems and cross-bridges. 
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Figure 4.2. The effects of cell wall binding domains (CBDs) on lytic activity and spectra. The 
binding affinity conferred by CBDs can help localize endolysins onto the cell wall surface for 
improved catalytic efficiency (a). Loss of CBDs may decrease access of the truncated enzymes 
to the cell wall and result in limited activity (b), but may also result in broader lytic spectrum by 
alleviating limitations of CBD specificity (c). Negatively charged EADs without CBDs may not 
efficiently bind and hydrolyze negatively charged peptidoglycan structures (d, left), while those 
with positive net charge may be much more active due to greater electrostatic compatibility (d, 
center). Even with functional CBDs, lysins with negatively charged EADs may be less active 
than those that carry net positive charges (d, right) — see [35] for further discussion. 
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CHAPTER 5: ANTILISTERIAL ACTIVITY BY ENDOLYSIN PLYP100 IS 
DEPENDENT ON CELL HISTORY AND ENVIRONMENT5 
5.1 ABSTRACT 
Listeria monocytogenes is highly problematic in the manufacture and processing of 
ready-to-eat foods due to its environmental persistence and its ability to grow under refrigerated 
storage. Special care must be taken to prevent listerial contamination during the production of 
fresh cheeses, as their delicate flavor and texture are incompatible with many of the 
antimicrobial processes and additives commonly used for other foods. Bacteriophage-derived 
cell wall hydrolytic enzymes, known as endolysins, comprise one possible intervention that may 
not suffer from the high strain specificity of their parent bacteriophages or the development of 
resistant strains. To address limitations of current antilisterial processes for fresh cheeses, we 
have assessed the antimicrobial efficacy of the Listeria bacteriophage endolysin PlyP100 in 
vitro. In doing so, we demonstrate the importance of culture environment and growth state on the 
sensitivity of target organisms. Furthermore, we show that PlyP100 exhibits a specificity for 
Gram-positive organisms with directly crosslinked peptidoglycan and displays considerable 
bacteriostatic activity against L. monocytogenes in a model cheese system for at least four weeks 
under refrigerated storage.  
Importance: Identifying novel preservation methods is a critical safeguard to the market 
expansion of foods at high risk for carrying pathogenic organisms, particularly when there are 
few viable alternatives. The commercial production of fresh Hispanic-style cheeses essentially 
relies on milk pasteurization, factory sanitation, and product refrigeration alone for the 
prevention of pathogenic contamination and outgrowth, the inadequacy of which is illustrated by 
the pervasiveness of Listeria monocytogenes plaguing the dairy industry. We show that the 
endolysin PlyP100 demonstrates considerable promise for preventing the propagation of L. 
monocytogenes in fresh cheeses. Moreover, we present several factors to consider in the study 
and application of bacteriophage endolysins in foods, including target specificity, cell history, 
and environmental tolerance, each of which significantly impacts antimicrobial potential.   
   
                                                 
5 This chapter has been submitted for publication to the journal Applied and Environmental Microbiology: Van 
Tassell M.L., Ibarra-Sanchez L.A., Hoepker G.P., Miller M.J., 2016. Antilisterial Activity by Endolysin PlyP100 is 
Dependent on Cell History and Environment. Elements of this chapter have been included in an abstract accepted 
for presentation at the 2016 International Association for Food Protection Annual Meeting in St. Louis, Missouri.  
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5.2 INTRODUCTION 
Listeria monocytogenes is a Gram-positive foodborne pathogen responsible for 
considerable harm to public health, particularly amongst the elderly, infants, pregnant women, 
and the immune-compromised. In these populations, infection can develop into deadly 
complications such as pneumonia, meningitis, septicemia, or uterine infections that can result in 
miscarriage or stillbirth. Dairy foods are linked to nearly one fourth of listeriosis cases, 
accounting for over $700 million in healthcare costs annually in the US alone (1). The majority 
of these cases are associated with soft cheeses, particularly fresh Hispanic-style cheeses and 
surface-ripened cheeses. 
These soft cheeses favor the growth of L. monocytogenes because, unlike most cheeses, 
they have relatively low acid content, high moisture, and are often consumed without cooking. 
Preservation treatments involving high heat or pressure can negatively impact the texture or 
ripening properties of these cheeses and few chemical preservatives are as effective within their 
pH range (2, 3). Such limitations, along with the ability of L. monocytogenes to tolerate high salt 
content and grow under refrigeration, leave few effective control measures for these types of 
cheese. Due to these risk factors and the severity of listeriosis, US regulations completely 
prohibit the presence of L. monocytogenes at any level in ready-to-eat foods and the EU prohibits 
it in any food that may support its growth. This results in incalculable economic loss to the dairy 
industry regarding product testing, product loss and recalls, as well as opportunity costs of not 
pursuing market expansion.  
Lytic bacteriophages (phages) have been pursued as a promising alternative antimicrobial 
application for inclusion in food products to target specific pathogens. Considerable reduction in 
listerial load has even been achieved in fresh cheeses (4, 5). Phages often feature narrow host 
spectra, however, with strain specificity limited to particular serovars. There are now broad-
spectrum commercial phage preparations approved for use in the US to inhibit L. monocytogenes 
in foods, but the development of strains resistant to phage infection can be problematic.  
One such commercial application was recently shown to elicit resistant isolates in a dairy 
environment, which highlights concerns over routine application of phages as a preventative 
measure (6). While this application involved a single phage strain, challenge studies have shown 
that even phage cocktails of multiple strains can result in the emergence of insensitive isolates (7, 
8). Bacteria can develop resistance to phages via a number of mechanisms, ranging from abortive 
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infection systems to alteration of cell surface receptor sites (9). After successful infection, 
however, lysis is evoked by viral hydrolytic enzymes referred to as endolysins. As endolysins 
target conserved peptidoglycan (PG) structures in the cell wall, they exhibit less strain specificity 
than parental phages and are widely considered to be unlikely to promote the development of 
resistance in target organisms (10–12). Exogenous applications of endolysins have thereby been 
of considerable interest as alternative treatments for Gram-positive pathogens, to overcome the 
limitations of antibiotics, phage therapies, and other antimicrobials. 
However, there has been little direct investigation of the interplay between environmental 
factors influencing cell physiology and endolysin efficiency. Such factors have direct 
implications on the efficacy of hydrolytic enzymes as antimicrobial preservatives in complex 
food environments and it would be of benefit to better understand what impacts lysin activity 
against pathogens in a food system. Furthermore, only a few studies have characterized the 
antimicrobial activity of endolysins in food applications, primarily in milk over only short 
periods of time (13). We wished to assess the activity of an endolysin as an antimicrobial 
preservative in a fresh cheese, queso fresco, for an elongated period under typical refrigerated 
storage, to reflect the nature of the problem posed by the gradual growth of L. monocytogenes 
contaminating such products. 
In a previous work, we developed a miniature fresh cheese model for assessing the 
efficacy of antimicrobials against Listeria (14). In this study, we report the characterization of 
the endolysin PlyP100, from L. monocytogenes phage P100, with regards to lytic activity under 
various conditions in vitro and show that antimicrobial efficacy is determined by factors of cell 
history. Furthermore, we incorporate PlyP100 into our model fresh cheese system to demonstrate 
its activity in situ as a food antimicrobial. 
5.3 MATERIALS AND METHODS 
5.3.1 Bacterial Strains and Culture Conditions. 
Bacterial strains (Table 5.1) were recovered from frozen glycerol stock (-80°C) by 
subculturing twice in growth media prior to preparation for each assay. Listeria, Enterococcus, 
and Aerococcus spp. were cultured aerobically with shaking (250 RPM) in Brain Heart Infusion 
broth (BHI; Becton, Dickinson and Co.) at 37°C. Lactobacillus spp. were cultured anaerobically 
at 37°C in MRS broth (Becton, Dickinson and Co.), while Carnobacterium divergens was 
cultured anaerobically at 30°C in MRS and Bifidobacterium bifidum was cultured anaerobically 
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at 37°C in MRS supplemented with 0.5% w/v L-cysteine. Leuconostoc mesenteroides and 
Weisella confusa were incubated aerobically without shaking at 26°C in MRS and Lactococcus 
spp. were incubated aerobically without shaking at 30°C in M17 broth (Oxoid) supplemented 
with 0.5% lactose. Clostridium spp. were incubated anaerobically at 37°C in Reinforced 
Clostridial Medium (Becton, Dickinson and Co.). Bacillus subtilis and Staphylococcus aureus 
were grown aerobically with shaking in tryptone-yeast extract-glucose broth (5 g/L tryptone, 5 
g/L yeast extract, 1 g/L K2HPO4, 1 g/L glucose), while Brevibacterium linens was grown in the 
same medium at 26°C aerobically without shaking. Escherichia coli BL21 (DE3) was used for 
endolysin expression and cultured in LB broth or agar (Fisher Scientific) and transformants were 
selected in the same medium supplemented with 50 mg/L ampicillin. 
5.3.2 Generation of Purified Recombinant PlyP100 Enzyme. 
Using the sequence reported in the NCBI Genbank database (DQ004855.1), endolysin 
gene plyP100 was chemically synthetized and subcloned by Life Technologies (Thermo Fisher 
Scientific) into expression vector pRSET B. Competent E. coli BL21 (DE3) was transformed 
with the resulting plasmids via transformation protocol using calcium chloride (15). 
Transformants were grown aerobically with shaking (250 rpm) to mid-log phase at 37°C in LB 
broth (Fisher Scientific) with 50 mg/L ampicillin, then induced with 1 mM isopropyl-β-D-
thiogalactopyranoside. Cultures were then incubated for 20 hours at 25°C, pelleted via 
centrifugation at 4000 × g for 30 min at 4°C, washed in phosphate buffered saline (PBS; KCl 
200 mg/L, KH2PO4 200 mg/L, NaCl 8 g/L, Na2HPO4 1.15 g/L, pH 7.2), and frozen overnight at -
20°C. Recombinant endolysins were purified from the cell pellets using the QIAexpress Ni-NTA 
Fast Start Kit (Qiagen) according to the manufacturer’s instructions. Purified PlyP100 was 
dialyzed into PBS via an Amicon Ultra-15 10K Centrifugal Filter Unit (Merck Millipore) and 
diluted with an equal volume of glycerol, followed by sterile-filtration and storage at -20°C. 
Protein purity was confirmed via SDS-PAGE, with only a single band visible of the expected 
size, and quantified via the Quick Start Bradford Protein Assay (Bio-Rad) prior to use. 
5.3.3 Lytic Assays. 
Cultures of target organisms were grown to a desired culture density and harvested via 
centrifugation, followed by two washes in buffer and re-suspension to a standardized optical 
density at 600 nm (OD600). Cell suspensions were prepared in PBS and combined 1:1 in 
microtiter plates with 20 µg/mL of PlyP100 in PBS and incubated for 30 min at 30°C, unless 
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noted otherwise. Suspensions combined with buffer alone were used as untreated controls for 
each experimental treatment. OD600 was measured immediately following mixture of the samples 
and after 30 minutes. Lytic activity was calculated as the percentage decrease in OD600 of treated 
samples, corrected for any decrease in OD600 of the controls. Activity between treatment 
conditions was reported as a percentage of the treatment with the highest activity, which was set 
at 100%. 
To determine enzymatic specificity, assays were carried out as described above with 
cultures of the strains listed in Table 5.1, grown overnight then washed with PBS and heat-killed 
(121°C for 20 min) to maximize lytic activity and thereby sensitivity of the assay to detect 
susceptibility of each strain. Suspensions were then adjusted to OD600 of 1.0 and challenged with 
a final concentration of 2.5 µg/mL PlyP100. The remaining in vitro lytic assays were carried out 
with the non-pathogenic L. innocua ATCC 33090 based on its comparable lytic activity to the L. 
monocytogenes strains tested. 
To assess the impact of salt concentration, pH, and temperature on lytic activity, assays 
were carried out as described above against L. innocua grown to late-log phase in BHI, washed 
in PBS and stored at -20°C until used. To vary salt concentration, cells were prepared in 
phosphate buffers with formulae adjusted to concentrations of 0 to 500 mM NaCl. To control 
pH, a series of boric-phosphoric acid buffers were prepared comprised of 40 mM boric acid and 
40 mM phosphoric acid, titrated with sodium hydroxide to pH 3 to 11. Boric-phosphoric buffers 
were prepared with NaCl concentrations comparable to that of PBS. To assess the impact of 
temperature on lytic activity, cell suspensions and buffers were pre-incubated and incubated 
between measurements at a given temperature of 4°C to 50°C.  
To assess the activity of PlyP100 against cells derived from different growth phases, 
cultures of L. innocua were grown to early-log, mid-log, late-log, and stationary phases, 
corresponding to OD600 of 0.25, 0.5, 1.0, and 1.6 in BHI and 0.15, 0.3, 0.6, and 0.75 in LB, 
respectively. Cultures were also prepared after overnight growth, to approximately OD600 1.7 in 
BHI and 0.85 in LB. Turbidity reduction assays were carried out as described above, 
immediately following cell harvest and washing in buffer. The pH of culture supernatants were 
measured at each growth phase to monitor the acidity of the cell growth environment and 
progression of each fermentation. Cell size was assessed microscopically at each growth phase to 
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detect the occurrence of a stress response that may dramatically alter the size or shape of cells, 
such as filamentation. 
Fresh L. innocua was also challenged with dilutions of PlyP100 ranging from 0 to 300 
µg/mL in MIC and spot on lawn assays as described by Nelson et al. (16) to assess antimicrobial 
activity against growing cells. For assessing the impact of growth rate on endolysin sensitivity, 
MIC and spot-on-lawn assays were also performed using 2 to 100-fold dilutions of BHI and BHI 
agar. All lytic assays were carried out in at least triplicate independent experiments. 
5.3.4 PlyP100 Activity in Fresh Cheese. 
The sensitivity of L. monocytogenes to PlyP100 in a food system was modeled via their 
incorporation into miniaturized laboratory fresh cheeses as described previously (14). Briefly, 
pasteurized whole milk was used to prepare multiple small batches of queso fresco, each 
reflecting commercial fresh cheeses with approximately 1% salt, 45% total dry matter, and pH 
6.5, due to lack of starter culture or ripening process. To incorporate endolysin treatments to the 
cheeses, PlyP100 was added to the milk prior to renneting, at a final concentration of 750 µg per 
g of cheese. Cheeses were challenged with washed suspensions of overnight L. monocytogenes 
culture incorporated into the curd prior to pressing, for a final concentration of approximately 5 
log CFU/g. The L. monocytogenes inocula were comprised of a cocktail of NRRL strains B-
33104, B33419, B-33420, B-33424, and B-33513, suspended to an equal ratio of cell densities. 
Cheeses with and without PlyP100 were stored at 4°C for up to 28 days and enumerated on 
PALCAM Listeria-Selective agar (EMD-Millipore) supplemented with 20 mg/L ceftazidime 
after 24 to 48 hour incubation at 37°C. Three independent experiments were performed with 
samples prepared in duplicate for each time point and plated in triplicate dilutions. 
5.3.5 Statistical Analyses. 
Measurements of culture pH and sensitivity to PlyP100 for each lytic assay were 
subjected to analysis of variance and post hoc separation of means by Tukey honest significant 
difference test (α = 0.05) using R (v3.2.4, R Project for Statistical Computing [http://www.r-
project.org/]). 
5.4 RESULTS 
5.4.1 Target Spectrum of PlyP100 Enzymatic Activity. 
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PlyP100 lysed each of the L. monocytogenes strains tested, across several serovars and of 
varied origin, as well as each strain of additional Listeria spp. tested (Table 5.1). Across a variety 
of lactic acid bacteria (LAB) and other Gram-positive organisms, PlyP100 was still partially 
active against several strains, including Lactobacillus plantarum, Aerococcus viridans, Bacillus 
subtilis, Clostridium difficile, and Brevibacterium linens. Bacillus subtilis, the target organism 
most closely related to Listeria (17), was as sensitive to PlyP100 as the listerial strains. The 
remaining susceptible strains were each approximately half as sensitive to PlyP100 as measured 
by turbidity-reduction assay.  
5.4.2 Environmental Impact on PlyP100 Enzymatic Activity. 
As environmental conditions are important factors in enzymatic activity, we measured the 
impact of three key variables on the ability for PlyP100 to lyse listerial cultures grown in BHI 
then washed in test buffer. Under optimal conditions, the concentrations of PlyP100 tested could 
generally elicit a 70 to 80% reduction in turbidity in 30 min. The optimal pH for activity of 
PlyP100 was approximately pH 8 (Fig. 5.1A), with little activity observed below pH 6 or above 
pH 10. PlyP100 displayed an optimal salt-concentration of approximately 100 to 150 mM NaCl 
in phosphate buffer (Fig. 5.1B), with decreased activity at 500 mM NaCl and low activity in the 
absence of salt. PlyP100 also demonstrated a mesophilic temperature optimum (Fig. 5.1C), with 
activity declining at temperatures below 37ºC, but stable up to 50°C.  
5.4.3 PlyP100 Activity Relative to Cell History. 
To elaborate how differences in cell growth and preparation may relate to sensitivity 
towards hydrolytic enzymes, we assessed the activity of PlyP100 against cell suspensions of 
equal density from cultures grown to various stages of growth in different media. Cells cultured 
in BHI increased in sensitivity to PlyP100 over the course of logarithmic growth, until losing 
sensitivity at stationary phase (Fig. 5.2). Cells cultured in LB did not increase as much over 
logarithmic growth and lost sensitivity earlier, at late-log phase, revealing a significant 
interaction between growth phase and media (p < 0.001). Cultures exhibited marginally greater 
sensitivity to PlyP100 after overnight incubation relative to stationary phase, but this was not 
statistically significant. 
5.4.4 Change in Culture Across Growth Cycle.  
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To relate changes in the growth environment with sensitivity to endolysins, at each 
growth phase we also measured pH of the culture supernatant and observed the cells variation in 
gross morphology. No differences were observed in cell size or shape, so observations of lytic 
activity did not correspond to gross shifts in cell form such as cellular filamentation or stunting 
that some organisms exhibit. The pH of the cultures dropped significantly by mid- to late-log 
phase (Fig. 5.3). The pH of culture grown in LB began lower and remained lower through late-
log phase, but culture grown in BHI acidified further overall, likely due to the presence of 
glucose in the medium. Overall, culture grown in LB featured approximately a 30% lower 
growth rate, half the cell density, and half the decrease in pH of the culture grown in BHI. 
5.4.5 PlyP100 Activity Relative to Cell Growth Rate.  
Cells derived from a state of growth and assessed for enzymatic lysis in PBS can be 
highly sensitive, as described above. However, cells tested for sensitivity to PlyP100 in standard 
MIC or spot-on-lawn assays, using BHI to support growth, resulted in no detectable growth 
inhibition even at a concentration of 300 μg/mL of endolysin. However, heat-killed cells were 
highly sensitive to degradation by PlyP100 in BHI and LB, suggesting that the media were not 
inhibiting enzymatic activity directly. As such, we were unable to assess lytic activity of PlyP100 
against actively growing cells in LB or BHI. 
5.4.6 PlyP100 Activity in Fresh Cheese.  
As shown in Figure 5.4, L. monocytogenes grew well in untreated queso fresco under 
refrigerated storage at 4ºC, increasing from 5 to 8 log CFU/g in about two weeks. PlyP100 
appeared largely bacteriostatic, reducing cell viability by only about one half-log CFU/g from the 
starting inoculum, but preventing further growth for over three weeks. As such, treatment with 
PlyP100 resulted in approximately a 3.5 log CFU/g reduction relative to the untreated control by 
the end of four weeks.  
5.5 DISCUSSION 
5.5.1 The PlyP100 Lytic Spectrum Suggests Peptidoglycan Specificity.  
An ideal antilisterial should be able to target all possible strains of Listeria, but interfere 
with few other organisms. PlyP100 is an N-acetylmuramoyl-L-alanine amidase (18), targets a PG 
linkage that is relatively conserved across all bacteria, so to determine the breadth of its lytic 
spectrum we compared its activity against a variety of Listeria and other Gram-positive bacteria 
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relevant to foods. PlyP100 comparably degraded each serovar of Listeria tested (Table 5.1), so 
its activity is unlikely mediated by binding directly to teichoic acid structures that vary amongst 
serovars like several other listerial phage endolysins that have been characterized (19, 20). 
Among all organisms tested, PlyP100 only affected strains of Schleifer & Kandler (21) PG group 
A1, characterized by direct interpeptide cross-linkage between glycan chains. The presence of 
different cross-bridging structure appears to prevent access of the PlyP100 catalytic site to the 
target N-acetylmuramoyl-L-alanine linkage, possibly by steric hindrance from a conserved cell-
binding site on the interpeptide cross-linkage. These observations are consistent with the 
specificity of other homologous enzymes, including the listerial phage endolysins LysZ5 (22) 
and Ply511 (23).  
5.5.2 The Environmental Optima of PlyP100 in vitro Suggest Specific Limitations.  
To assess the plausibility of PlyP100 as an antimicrobial for use in food systems, we also 
characterized the impact of several relevant environmental variables on the enzymatic activity of 
PlyP100 against a single substrate (Figure 5.1). PlyP100 activity exhibited a pH profile similar to 
that of Ply511 (24), with an optimum of approximately pH 8. Minimal activity was observed at 
pH 5, indicating that PlyP100 may not be a viable option in acidified foods. However, most 
unripened fresh cheeses maintain a pH around 6 (25, 26), which is not acidic enough for the 
effective use of many preservatives at low concentration (27). PlyP100 activity was also high 
within the range of salt content seen in many fresh cheeses (25), about 1 to 2% or up to about 
350 mM NaCl. Furthermore, while PlyP100 activity declined below 37°C, it remained high up to 
50°C, so enzymatic activity should be maintained throughout the temperatures of cheese 
manufacture. 
5.5.3 Sensitivity to PlyP100 is Dictated by Cell History and Physiology.  
Growth phase dependency of lytic sensitivity has been infrequently characterized and is 
still not clearly understood (28, 29), so we sought to elaborate elements of how cell preparation 
may contribute to endolysin sensitivity. Cultures grown in BHI increased in sensitivity to 
PlyP100 over the course of exponential growth (Figure 5.2), declining abruptly in sensitivity 
upon stationary phase, while culture grown in LB lost sensitivity at late-log phase. The former 
parallels observations made of a streptococcal endolysin (28), while the latter is more consistent 
with the observations of a Bacillus phage endolysin (29). Clearly, our data demonstrate that 
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endolysin sensitivity is driven in part by both the cell cycle and the environment in which the 
cells are grown. 
Numerous environmental factors affecting cellular physiology during growth could have 
affected sensitivity to PlyP100, even when cells are washed into a buffered suspension. Such 
factors could include nutrient limitation impacting wall teichoic acid (30, 31) and PG 
composition (32–34), osmolyte accumulation affecting cell turgor and surface stress (35–37), or 
pH affecting modification of the cell envelope (38, 39). The decline in pH observed through 
exponential growth (Figure 5.3) corresponded to a general increase in sensitivity to PlyP100, and 
the more rapid change in pH of BHI cultures corresponded with the greater increase in 
sensitivity, until sensitivity was lost abruptly. Both cultures did demonstrate peak sensitivity 
when grown to approximately pH 6.5, but whether this was coincidental or representative of an 
environmental pH below which cells are likely to be less sensitive to PlyP100 is unclear.  
Considering the differences observed in growth between LB and BHI, cellular growth 
rate may also be important for sensitivity to enzymatic lysis. The amount of PG crosslinking and 
total cellular proportion of cell wall material have been correlated with growth rate (38, 40), both 
potentially affecting sensitivity to enzymolysis (41). The progressive increase in sensitivity to 
PlyP100 observed over log-phase in BHI may be driven by increased growth rate and a rising 
proportion of the cell population with polar cell walls immature from recent division (42-44).  
Cultures grown in LB exhibited both a lower growth rate and lower peak sensitivity to 
PlyP100. Unfortunately, in attempting to determine the minimum growth rate at which L. 
innocua is sensitive to lysis, we encountered a previously noted, yet unexplained phenomenon 
(16), by which otherwise highly active PG hydrolases appear unable to lyse cells in growth 
media. Paradoxically, PlyP100 appears to preferentially affect inert cells derived from a state of 
growth, but not effectively lyse actively growing cells in growth media, even at enzyme 
concentrations orders of magnitude greater than those effective against inert or heat-killed log-
phase cells. 
 We hypothesize that this observation is related to the pH gradient across the cell 
envelope established by the generation of proton-motive-force. The immediate cell exterior could 
be up to 4 pH units lower than the surrounding environment (45), which decreases the stability 
and efficiency of many enzymes closer to the membrane, including autolysins (39, 46). If 
PlyP100 is also inhibited by this acidity, it may be unable to elicit sufficient damage to the 
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acidified cell wall interior to result in lysis of growing cells. Upon removal from a nutritive 
environment to a buffer system, cultures may experience a loss of this surface pH gradient, 
resulting in artificial sensitivity to enzymatic lysis. Endolysins would not have experienced 
evolutionary pressure to maintain low-pH activity for this method of lysis, having the benefit of 
escorting holin proteins that not only grant access to the PG through the cell membrane from 
within, but create localized disruption of the pH gradient in doing so (47). This pH limitation 
may actually be evolutionarily advantageous, to prevent indiscriminate lysis of neighboring 
uninfected hosts, much as has been proposed of the high-strength affinities of some endolysin 
cell-binding domains (19, 48). This hypothesis is supported by the discrepancies observed 
between activities of PlyP100 in media and PBS, as well as its minimal activity below pH 6, but 
more sophisticated approaches to investigating spatiotemporal changes in cell physiology would 
be required to elaborate further. 
5.5.4 PlyP100 is Bacteriostatic against L. monocytogenes in Fresh Cheese.  
There are clearly several factors influencing cell surface biochemistry and enzymatic 
activity, which emphasizes the necessity of practical in situ validation of antimicrobial 
applications in target environments. Therefore, we inoculated fresh cheeses containing PlyP100 
with a cocktail of food- and human-isolates of foodborne outbreak-associated L. monocytogenes 
strains. We observed a bacteriostatic effect: under refrigerated storage at 4 ºC, PlyP100 inhibited 
listerial growth for four weeks – a typical shelf life for queso fresco. A dramatic reduction in 
viability of the inocula was not observed, perhaps because the cheese matrix limited lytic activity 
by obstructing physical access of the enzymes to target cells. In soya milk, where enzyme 
mobility was likely much higher, LysZ5 was shown to elicit greater inhibition of listerial 
viability (22).  
Moreover, further reduction of listerial viability by PlyP100 may not have been seen due 
to its relative inability to kill rapidly growing cells or uninjured, but non-replicating cells. Our 
initial in vitro results suggested that PlyP100 might not have been able to inhibit growing cells in 
cheese, as activity was low at 4°C and we did not observe growth inhibition in MIC or spot-on-
lawn assays. However, Listeria in fresh cheese may have remained in a “Goldilocks zone” of 
growth for inhibition by PlyP100; Listeria in queso fresco exhibited slow logarithmic growth, a 
cell state that we have shown to be more structurally prone to enzymatic lysis than non-growth, 
while refrigerated conditions that allow for only a 50-hour doubling time in the absence of 
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PlyP100 may also slow metabolic activity sufficiently to offset the lower enzymatic activity at 
4°C and allow for the selection of non-growing cells by enzymatic lysis. 
Overall, PlyP100 is effective at inhibiting the growth of Listeria in laboratory fresh 
cheeses and warrants follow-up for further application in dairy manufacturing. PlyP100 appears 
largely compatible with dairy products in terms of environmental tolerance and microbial 
specificity; not only will it likely inhibit the majority of, if not all, listerial strains, but seems 
unlikely to negatively impact the desirable bacteria native to most dairy fermentations based on 
our observations of specificity. Mold-ripened cheeses predisposed to listerial proliferation due to 
surface de-acidification may benefit from endolysin application. An endolysin of such broad 
spectrum may also be advantageous for the prevention of dairy spoilage, targeting the equivalent 
PG structure in the Bacillaceae that comprise a majority of common Gram-positive isolates of 
spoiled dairy (49). 
Lastly, we have also shown that cell history and physiology are crucial factors governing 
sensitivity to exogenous endolysins. It is therefore essential to account for various environmental 
factors, including methods of cell preparation, in the assessment of endolysin activity, both in 
vitro and in situ. The manufacturing environment and nature of available growth substrates could 
have a dramatic impact on sensitivity of foodborne pathogens to endolysin treatments. Future 
works should focus on elaborating the mechanisms of physiological response to these 
environmental cues as they pertain to lysin sensitivity, optimization via protein engineering (50), 
or combination with potentiating agents or synergistic antimicrobials. 
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5.8 TABLES AND FIGURES 
Table 5.1. Lytic spectrum of PlyP100 against Gram-positive bacterial strains used in this work.  
Family Species Strain ID Sensitivitya PGb Serovar 
Listeriaceae 
 
 
  
 
Listeria monocytogenes 10403S 1.00 ± 0.02 A1γ 1/2a 
 
 
SLCC-5764 0.96 ± 0.03 A1γ 1/2a 
 
 
NRRL B-33419 0.97 ± 0.04 A1γ 1/2a 
 
 
NRRL B-33395 1.00 ± 0.02 A1γ 1/2a 
 
 
NRRL B-33391 0.91 ± 0.04 A1γ 1/2b 
 
 
NRRL B-33424 0.89 ± 0.02 A1γ 1/2b 
 
 
ATCC 7644 0.98 ± 0.01 A1γ 1/2c 
 
 
ATCC 19112 1.04 ± 0.03 A1γ 1/2c 
 
 
NRRL B-33393 1.01 ± 0.03 A1γ 3b 
 
 
NRRL B-33226 0.97 ± 0.02 A1γ 3c 
 
 
NRRL B-33403 1.04 ± 0.05 A1γ 4a 
 
 
ATCC 13932 0.95 ± 0.01 A1γ 4b 
 
 
NRRL B-33420 0.97 ± 0.01 A1γ 4b 
 
 
NRRL B-33513 0.90 ± 0.05 A1γ 4b 
 
 
NRRL B-33104 1.00 ± 0.01 A1γ 4b 
 
 
NRRL B-33231 0.89 ± 0.05 A1γ 4b 
 
 
NRRL B-33116 1.00 ± 0.04 A1γ 4c 
 
 
NRRL B-33120 0.93 ± 0.02 A1γ 4d 
 
Listeria innocua ATCC 33090 1.03 ± 0.03 A1γ 4e 
 
Listeria innocua NRRL B-33409 1.07 ± 0.04 A1γ 6a 
 
Listeria ivanovii subsp. ivanovii NRRL B-33017 0.96 ± 0.04 A1γ 3a 
 
Listeria welshimeri NRRL B-33020 0.99 ± 0.01 A1γ 5 
 
Listeria seeligeri NRRL B-33019 1.05 ± 0.03 A1γ 6b 
Lactobacillaceae 
 
   
 
Lactobacillus delbrueckii subsp. bulgaricus ATCC 11842 0.10 ± 0.06 A4α  
 
Lactobacillus casei ATCC 393 0.15 ± 0.02 A4α  
 
Lactobacillus plantarum ATCC 8014 0.44 ± 0.11 A1γ  
 
Lactobacillus fermentum NRRL B-1840 0.11 ± 0.02 A4β  
 
Lactobacillus brevis NRRL B-4527 0.01 ± 0.13 A4α  
 
Lactobacillus rhamnosus ATCC 53103 0.16 ± 0.11 A4α  
 
Pediococcus acidilactici NRRL B-14958 0.05 ± 0.03 A4α  
Carnobacteriaceae 
 
   
 
Carnobacterium divergens NRRL B-14830 0.08 ± 0.04 A1γ  
Enterococcaceae 
 
   
 
Enterococcus faecium ATCC 6057 0.00 ± 0.05 A4α  
Aerococcaceae 
 
   
 
Aerococcus viridans ATCC 11563 0.48 ± 0.05 A1α  
Streptococcaceae 
 
   
 
Lactococcus lactis subsp. cremoris ATCC 19257 0.03 ± 0.12 A4α  
 
Lactococcus lactis subsp. lactis ATCC 19435 0.03 ± 0.04 A4α  
Leuconostocaceae 
 
   
 
Leuconostoc mesenteroides NRRL B-1118 0.10 ± 0.01 A3α  
 
Weissella confusa NRRL B-1064 0.09 ± 0.05 A3α  
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Table 5.1. (cont.) 
Family Species Strain ID Sensitivitya PGb Serovar 
Bacillaceae 
 
   
 
Bacillus subtilis NRRL NRS-744 0.94 ± 0.16 A1γ  
Clostridiaceae     
 
Clostridium difficile ATCC 70057 0.53 ± 0.07 A1γ  
 
Clostridium perfringens ATCC 13124 0.21 ± 0.08 A3γ  
Staphylococcaceae     
 
Staphylococcus aureus NRRL B-767 0.09 ± 0.03 A3α  
Bifidobacteriaceae     
 
Bifidobacterium bifidum NRRL B-41410 0.06 ± 0.17 A4β  
Brevibacteriaceae     
  Brevibacterium linens NRRL B-4210 0.49 ± 0.06 A1γ  
a Sensitivity to PlyP100, as measured by turbidity reduction of heat-killed cell suspensions incubated with the 
enzyme (2.5 µg/mL) for 30 min, relative to L. monocytogenes 10403S  
b Peptidoglycan chemotype subgroup of the strain’s cell wall, according to (21, 51)  
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Figure 5.1. Optimal environmental conditions for lytic activity of PlyP100. The optimal (A) pH, 
(B) salt concentration, and (C) temperature for the lysis of L. innocua ATCC 33090 were 
characterized via turbidity reduction assay over 30 min using 10 µg/mL PlyP100. The optimal 
activity for each variable was set as 100%. Bars indicate the mean ± standard error of triplicate 
independent experiments. Values sharing a letter within each section are not statistically different 
(P < 0.05). 
 
 
 
Figure 5.2. Lytic activity of PlyP100 against L. innocua ATCC 33090 by growth phase. Cells 
were subjected to turbidity reduction assay after harvesting at the indicated points of their growth 
in BHI (closed bars) and LB (open bars). Bars indicate the mean ± standard error of turbidity 
reduction relative to untreated controls for triplicate independent experiments. Values sharing a 
letter are not statistically different (P < 0.05). 
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Figure 5.3. Growth of Listeria in LB and BHI and corresponding changes in culture pH. L. 
innocua ATCC 33090 cultured in BHI (closed circles) grows to approximately twice the culture 
density of L. innocua cultured in LB (closed diamonds). The pH of culture in BHI (open circles) 
starts higher, but drops more rapidly than culture grown in LB (open diamonds). Values are 
means ± standard error of triplicate independent experiments. 
 
 
 
Figure 5.4. Antimicrobial activity of PlyP100 against L. monocytogenes in a fresh cheese model 
over four weeks of storage at 4°C. The enzyme was added to cheeses by weight, with final 
concentrations of 0 (open circle) and 750 (closed circle) µg/g PlyP100. Values are means ± 
standard error of triplicate independent experiments. 
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS  
In Chapters 1 and 2, I have shown that glycan-mediated bacterial interactions could be 
more closely evaluated. The model I’ve developed for whole-cell affinity chromatography can be 
adapted to suit numerous applications, thanks to its straightforward construction. The 
chromatography resin can accommodate functionalization with any reducing carbohydrate 
structure and maintain its conformational integrity, allowing for the investigation of numerous 
potential interactions. I have provided further evidence that Campylobacter jejuni adheres in 
some capacity to fucosylated structures, which may contribute to its persistence in poultry. The 
most anticipated direction in which to leverage these interactions for food safety would be to 
feed a non-digestible fucosylated glycan, such as 2FL, as a competitive exclusion agent to 
prevent the colonization of Campylobacter in poultry. Unfortunately, 2FL is still prohibitively 
expensive and is challenging to biosynthesize at sufficient scale for an appropriate animal 
challenge study.  
Screening for lactobacilli with adhesive capacity for 2FL using the affinity 
chromatography model has been unfruitful, possibly due to a lack of such phenotypes in these 
organisms. However, screening from a broader pool of organisms, such as those from the ceca of 
healthy, uninfected poultry, may provide a sufficiently diverse reservoir for the isolation of a 
competitive adhesion interaction. Furthermore, modulating the structures present in affinity 
chromatography may facilitate a deeper understanding of bacterial mechanisms of adhesion by 
describing to what extent specific oligosaccharide constituents of mucus contribute to pathogen 
adhesion. This knowledge could be used for targeted therapeutics, possibly via dietary means or 
direct-fed microbials.  
In Chapters 3 through 5, I have described the development and use of a small-scale fresh 
cheese model that can discriminate the efficacy of antimicrobials using minimal resources and 
maintain biocontainment of pathogenic contaminants in a user-friendly, relatively high-
throughput manner. I also demonstrated the potential that endolysins have for contributing to the 
food safety of a commodity in growing demand. Furthermore, I have highlighted ways that cell 
history is important for susceptibility of target contaminants, which carry implications for both 
interpretation of the literature as well as the design and implementation of endolysin applications 
in food. 
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To extend the impact of my research in an applied fashion, I would propose that the 
activity of PlyP100 be confirmed in additional products such as smear-ripened or mold-ripened 
cheeses. These cheeses are also more commonly contaminated with Listeria due to de-
acidification that takes place during surface ripening. It would be simple to assess the efficacy of 
the endolysin using commercially prepared cheeses challenged in vitro with Listeria, perhaps in 
collaboration with a dairy to facilitate both pre- and post-ripening assessment. Development of a 
miniaturized model of these types of cheese similar to the MLQF model may also be feasible. 
For a broader, more fundamental approach to extrapolating my work inhibiting Listeria 
with endolysins, I would propose a targeted screening and bioengineering of endolysins to 
optimize their efficacy in food matrices. Numerous diverse bacteriophages of L. monocytogenes 
have been identified, though few have been characterized in depth. Some may have a 
temperature profile resulting in greater activity under refrigeration or a pH range or target 
specificity more amenable to other varieties of cheese or food products. Some may just have 
higher catalytic efficiencies, but as of yet we do not have the capacity to predict these parameters 
without direct assessment. However, effective endolysins could be bioengineered to alter their 
structural characteristics, such as size, charge, or conformation, to optimize their diffusivity 
through food matrices or improve their environmental tolerance.  
Considerable work remains before successful commercial application of recombinant 
endolysins can be seen in foods, including matters of scale, cost-efficiency, and regulatory 
approval. However, this work has contributed to our understanding of their effect in fresh 
cheeses and provided proof-of-concept for their implementation, as well as a tool for further 
investigation of antimicrobial measures in fresh cheeses and their enhancement. 
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APPENDIX A: SUPPLEMENTAL POSTER 
Figure A.1. This research poster was prepared as a requirement for the 2012 College of ACES 
Summer Research Opportunities Program by Leilany Vásquez-Portalatín under my advisement 
and supervision. This poster represents the initial proof-of-concept testing of the miniaturized 
laboratory queso fresco model presented in Chapter 3; either nisin, the nisin-containing 
commercial preparation Nisaplin®, or the novel bacteriocin haloduracin (courtesy of Dr. Wilfred 
van der Donk) were incorporated to compare their antimicrobial activity against Listeria innocua 
over a 2-week refrigerated storage. Data for the treated cheeses were presented in the poster prior 
to recording the final time-points due to time-constraints of the summer research program. The 
data suggest that Nisaplin® and purified nisin provide comparable antimicrobial activity. It is 
unclear why haloduracin shows negligible effect against Listeria in cheese while otherwise 
effective in vitro, however it may be due in part to the 2-component nature of its structure, 
requiring a particular molar ratio interacting with target cells to effect cell death, which is 
prevented by the cheese structure. Similarly, haloduracin may be sequestered by direct 
interactions with fat globules or the protein matrix. Further investigation with haloduracin was 
not pursued due to both lack of efficacy and discontinued interest in its commercial applicability 
because of evidence from the van der Donk lab suggesting its potential toxicity to humans – a 
trait shared with other 2-component lantibiotic cytolysins. 
The file for the poster and dataset can be found at: S:\Miller Lab\Former Lab Members\SROP 2012  
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APPENDIX B: COLLABORATIVE RESEARCH PUBLICATIONS 
 
Figure B.1. This research article was the result of a collaboration that characterized the impact 
of probiotic bacteria and fava bean starch as supplements in fresh Hispanic-style cheese (Queso 
Panela). The study demonstrated the feasibility of including probiotic bifidobacteria that 
maintain viability over the shelf-life of the cheese, but that fava bean starch would not be an 
acceptable prebiotic to include in Panela. I was uninvolved with the experimental design, data 
collection, or interpretation, but was the individual primarily responsible for writing and revision 
of the manuscript during its preparation and throughout the peer-review process. 
Escobar M, Van Tassell ML, Martínez-Bustos F, Singh M, Castaño-Tostado E, Amaya-Llano S, 
Miller M. Characterization of a Panela Cheese with Added Probiotics and Fava Bean Starch. J. 
Dairy Sci., 2012, 95(6), 2779-87. This article is available from http://www.sciencedirect.com and 
DOI: 10.3168/jds.2011-4655.  
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Figure B.2. This research article was the result of a collaboration that surveyed the diversity of 
Lactococcus lactis isolates from different Tuscan dairies and their traditional sheep-milk cheeses 
(Pecorino Toscano). The study demonstrates via multi-locus sequence typing and various 
physiological measures that the regionality of protected designation of origin cheeses is reflected 
in the intraspecies genetic and phenotypic diversity of native microbiotia. I contributed to the 
design of aspects of the study, supervised A. Lee in the collection of experimental data, assisted 
with data analyses and interpretation, and was the primary writing contributor during its 
preparation and through peer-review. 
Turchi B, Van Tassell ML, Lee A, Nuvoloni R, Cerri D, Miller MJ. Short Communication: 
Phenotypic and genetic diversity of wild Lactococcus lactis isolated from Traditional Pecorino 
cheeses of Tuscany. J. Dairy Sci., 2013, 96(6), 3558-63. This article is available from 
http://www.sciencedirect.com and DOI: 10.3168/jds.2012-6518. 
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Figure B.3. This research article was the result of a collaboration that investigated the effects of 
a human milk oligosaccharide on the gut microbiota of infants. The study shows how the 
consumption of human milk oligosaccharides, particularly 2-fucosyllactose, impacts the 
bifidobacterial communities of newborns. I coordinated the preparation of purified biosynthetic 
2-fucosyllactose for use by collaborators for in vitro demonstration of bifidobacterial 
fermentation, as well as assisted with editing the manuscript. 
Lewis ZT, Totten SM, Smilowitz JT, Popovic M, Parker E, Lemay DG, Van Tassell ML, Miller 
MJ, Jin Y-S, German JB, Lebrilla CB, Mills DA. Maternal Fucosyltransferase 2 Status Affects 
the Gut Bifidobacterial Communities of Breastfed Infants. Microbiome, 2015, 3(13). This article 
is available from http://www.biomedcentral.com and DOI: 10.1186/s40168-015-0071-z. 
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Figure B.4. This perspective article was the result of a collaboration that investigated the impact 
of broccoli consumption on the metabolic properties of the cecal microbiota of rats. The study 
provides a critique on the literature of glucosinolate metabolism and shows that dietary 
glucosinolates select for microbial populations in the rat cecum that can hydrolyze glucosinolates 
to form bioactive isothiocyanates. I assisted with experimental design and sample handling for 
data collection, as well as editing of the manuscript. 
Angelino D, Dosz EB, Sun J, Hoeflinger JL, Van Tassell ML, Chen P, Harnly JM, Miller MJ, 
Jeffery EH. Myrosinase-dependent and –independent formation and control of ‘toxic’ 
isothiocyanate products of glucosinolate hydrolysis. Frontiers Plant Sci., 2015, 6:831. This 
article is available from http://www.frontiersin.com and DOI: 10.3389/fpls.2015.00831. 
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APPENDIX C: MANUSCRIPT MODIFICATIONS 
This appendix accounts for modifications made during the peer review process to the 
manuscript that comprises Chapter 5 – specifically the removal of sections pertaining to the use 
of microbial adhesion to solvents for characterizing surface properties of Listeria. They have 
been included here for posterity. 
 
METHODS 
Microbial Adhesion to Solvents. Microbial adhesion to solvents (MATS) was tested following 
the methods of Briandet et al. (1) with minor modifications to culture volumes. Suspensions of L. 
innocua were prepared by harvesting cells from early-log, mid-log, late-log, and stationary 
phases, as well as overnight (24h) culture, washing thrice in PBS, and resuspending to an optical 
density at 405 nm (OD405) of 0.35 (A0), approximately 108 CFU/mL. 150 µL aliquots of 
chloroform, hexadecane, decane, or ethyl acetate were added to 900 µL samples of each cell 
suspension and vortexed to mix for 60s. The mixtures were allowed to stand for 10 min to allow 
for the two phases to completely separate, then three 200 µL samples of the aqueous phase were 
carefully removed for measurement of OD405. The adhesion to each solvent phase was then 
calculated as (1 − 𝐴/𝐴0) × 100%. Hydrophobicity was calculated as the adhesion to 
hexadecane, while surface acidity was calculated as the adhesion to chloroform minus that to 
hexadecane and basicity was calculated as the adhesion to ethyl acetate minus that to decane. 
Experiments were performed with triplicate independent cultures. 
RESULTS 
Change in Culture Across Cell Cycle. To characterize surface properties of cells grown in 
different media across cell cycle progression, we partitioned the cultures based on their affinity 
to monopolar and apolar solvents of comparable intermolecular attraction (MATS). Chloroform 
is an acidic (electron-accepting) solvent, while ethyl acetate is a basic (electron-donating) 
solvent. The apolar solvents hexadecane and decane exhibit similar Lifshitz-van der Waals 
surface tension to each, respectively. Therefore, affinity to chloroform relative to hexadecane is 
indicative of basic cell surface properties and affinity to ethyl acetate relative to decane indicates 
acidic character, while adhesion to hexadecane is a common measure of hydrophobicity. 
Thus, across their growth cycle, listerial cells generally featured a high cell surface 
basicity (Table C1). The surface acidity of the cultures was comparatively very low, though 
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increased as cultures reached stationary phase. Cells cultured in LB exhibited a relatively 
constant and slightly higher hydrophobicity than those cultured in BHI. Changes in neither 
hydrophobicity nor surface acidity directly reflected sensitivity to PlyP100 at each growth phase. 
The increase in surface acidity at late-log phase in LB, which corresponds to the loss of 
sensitivity to PlyP100, wasn’t significantly higher than at mid-log phase. Similarly, culture from 
late-log phase in BHI exhibited twice the sensitivity to PlyP100, but displayed comparable 
surface acidity, and hydrophobicity did not significantly differ after early-log.  
To relate changes in cell surface affinity to growth environment, we also measured pH of 
the culture supernatant and average cell size at each growth phase. The average cell length was 
not significantly different between growth media or across growth phases, averaging 1.9 ± 0.4 
µm in BHI and 2.2 ± 0.5 µm in LB, so observations of MATS were not likely related to cell size 
or surface-to-volume ratio. 
DISCUSSION 
Sensitivity to PlyP100 is Dictated by Cell History and Physiology. We sought to observe such 
changes in surface affinity via MATS. Zeraik and Nitschke (2) observed a greater degree of 
relative surface basicity due to lower hydrophobicity, as well as greater acidic character, in L. 
monocytogenes grown in lower-nutrient media. Briandet et al (1) observed a higher acidic 
property in cultures grown on glucose, however. Here we have shown a similar decrease in 
surface basicity, with a lower acidity in LB compared with BHI. Furthermore, we have shown 
that surface acidity varies throughout cell growth. However, this acidity did not correspond well 
with sensitivity to PlyP100 per se. While relative surface basicity may contribute to cell 
sensitivity, as it may be suggestive of cell wall turnover and exposed or immature PG (3), neither 
acidity nor basicity appear to be direct indicators. 
BIBLIOGRAPHY 
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FIGURES & TABLES 
Table C.1. Cell surface properties as measured by microbial adhesion to solvents (MATS). 
  Hydrophobicity  Basicity  Acidity 
Growth Phase  LB  BHI  LB  BHI  LB  BHI 
Early-log  52.9 ± 5.8a  33.6 ± 1.8a  10.8 ± 7.1a  30.5 ± 6.92a  -67.2 ± 5.7a  -32.5 ± 4.2abc 
Mid-log  55.4 ± 2.3a  47.6 ± 3.9b  8.5 ± 7.5a  17.7 ± 6.45a  -66.5 ± 4.9a  -51.0 ± 3.8a 
Late-log  52.2 ± 3.4a  50.0 ± 2.4b  18.3 ± 5.2a  18.2 ±5.44a  -48.2 ± 8.3a  -47.2 ± 3.6ab 
Stationary  59.6 ± 6.2a  41.9 ± 4.9b  13.9 ± 5.4a  25.2 ± 4.31a  -18.5 ± 9.3b  -21.8 ± 4.5bc 
Overnight  54.2 ± 5.2a  45.9 ± 6.9b  18.4 ± 5.6a  17.2 ± 5.06a  -43.5 ± 7.5ab  -9.6 ± 4.4c 
a-d Within a column, values sharing a letter are not statistically different (P < 0.05) 
Values are means ± standard errors of triplicate independent experiments. 
 
 
